Podcasts about neurodegenerative

Can't get the brain fog to lift? You might be missing a key piece of the puzzle.In this episode, Amy uncovers surprising triggers of brain fog and walks you through evidence-based solutions to sharpen your focus and protect your brain. Listen now for practical tips!What to Listen For[00:01:00] The 3 brain regions affected by brain fog [00:04:00] How indoor air quality and mold exposure might be hijacking your brain function[00:06:30] The surprising connection between noise pollution and accelerated cognitive decline[00:07:00] Why your lighting environment and screen time could be draining your mental energy[00:08:00] "Attention residue": How multitasking fragments your focus and depletes cognitive resources[00:09:00] When brain fog signals something more serious: Neurodegenerative diseases and metabolic disorders[00:13:00] The journaling method: How to track and identify your unique brain fog triggers[00:14:00] Elimination experiments: A systematic approach to testing what's really affecting your cognition[00:17:00] The complete RESTORED protocol: 8 essential pillars for optimizing brain health[00:19:00] The implementation secret: Why starting with just one easy habit is crucial for success[00:24:00] Identity-based habit formation: Shifting from "trying to" to "I am a person who"[00:27:00] Preview of next episode's focus-building techniques and attention trainingResources MentionedDownload the complete RESTORED Protocol Guide: moxie-club.com/restoredWatch Amy's masterclass on brain health through menopause: moxie-club.com/protectBook a personalized brain fog elimination strategy session: moxie-club.com/strategyGet Amy's book "Thoughts are Habits Too" for her framework on lasting habit change: thoughtsarehabitstoo.comBrain fog doesn't have to be your new normal. By systematically addressing the underlying factors and implementing the RESTORED protocol, you can reclaim your mental clarity and experience the joy of a sharp, focused mind again. Subscribe & Review in iTunesIf you like what you hear, please subscribe to my podcast.  I encourage you to do that today as I don't want you to miss an episode.  Click here to subscribe on iTunes!Now if you're feeling extra loving, I would be really grateful if you left me a review over on iTunes, too. Those reviews help other people find my podcast and they're also fun for me to go in and read. Just click here to review, select “Ratings and Reviews” and “Write a Review” and let me know what your favorite part of the podcast is.Thank you!RESOURCES: Register for the FREE Masterclass: 5 Keys to Protecting Your Brain Health Book a FREE Discovery Call with Amy Lang Order Amy's book Thoughts Are Habits Too: Master Your Triggers, Free Yourself From Diet Culture, and Rediscover Joyful Eating. Follow Amy on Instagram @habitwhisperer

About the Guest(s): Dr. Laura Standridge: Dr. Laura Standridge is a prominent functional chiropractor known for her expertise in pediatric neurological development and genetic disorders. She is board certified in neurofeedback and specializes in approaches that focus on neurodevelopmental assessments, particularly concerning mitochondrial function and primitive reflexes. Dr. Standridge has gained attention for her work with rare neurodegenerative disorders, particularly BPAN, following her son's diagnosis with the disease. Her professional journey is marked by a dedication to understanding and improving neurological health through innovative methods in functional and integrative healthcare. Episode Summary: In this enlightening episode of Functional Health Radio, Dr. Kristin Hieshetter delves deep into the pressing health crises in America, revealing that the country's life expectancy has not only plateaued but declined for both men and women. Despite the high per capita healthcare expenditure, conditions like heart disease and cancer remain prevalent, and children are increasingly diagnosed with chronic diseases. The discussion transitions into a heartfelt narrative with Dr. Laura Standridge, a functional chiropractor passionately occupied with her son Laird's rare neurodegenerative disease known as BPAN (Beta-propeller Protein-Associated Neurodegeneration). BPAN, characterized by iron accumulation in the brain, is a daunting diagnosis for any family, but Dr. Standridge shares her proactive approach to defy the medical script of decline. Employing advanced genetic testing and leveraging her deep understanding of functional health principles, Dr. Standridge explores comprehensive interventions that have led to remarkable outcomes for Laird. From dietary adjustments to specialized neurodevelopmental therapies and state-of-the-art medical interventions, Dr. Standridge's narrative underscores a hopeful perspective—not only sharing insights about BPAN but also reflecting innovative applications of functional health practices. This episode highlights how a blend of cutting-edge science and compassionate care can write new chapters in health and wellness narratives. Key Takeaways: BPAN Disease Insight: BPAN is a rare neurodegenerative disorder that causes abnormal iron accumulation in the brain, significantly impairing mitochondrial function and autophagy. Unique Case of Laird: Laird defies the typical BPAN trajectory through a tailored combination of nutritional strategies, functional therapies, and mitochondrial enhancement techniques. Importance of Nutrition: Laird's diet, free of gluten and inflammatory foods, supports brain health by preventing autoimmune responses that can exacerbate neurological damage. Integrative Approaches: Utilization of genetic testing and innovative therapies, like low-level laser therapy, provides neuroprotective benefits and enhances Laird's quality of life. Collaborative Healthcare: Dr. Standridge exemplifies the power of interdisciplinary collaboration, uniting various specialists to support a functional health-driven roadmap for Laird. Notable Quotes: "We are walking around in the most amazing, intelligent, responsive, adapting and aware system in the world, the human. Let's bring it to its fullest potential." - Dr. Kristin Hieshetter "It doesn't matter what the label is…I'm much more interested in how you are functioning and not what somebody from the outside might call you." - Dr. Laura Standridge "We waited and we waited and we waited some more and finally received this diagnosis." - Dr. Laura Standridge "The brain is built on the postural system…and so there is this amazing order of neurological development whether you have a genetic difference or not." - Dr. Laura Standridge "Together, we'll be the change that we wish to see in the world." - Dr. Kristin Hieshetter Resources: Learn more about BPAN and related genetic testing at the CDC Vital Statistics Report: www.cdc.gov For insights into functional chiropractic care and Dr. Laura Standridge's approaches, visit Functional Health Mastery Stay informed with the World Economic Forum's health expenditure data: www.weforum.org Functional Health Mastery Group Listen to the full episode to dive deeper into the revolutionary approaches that Dr. Laura Standridge and Dr. Kristin Hieshetter share in tackling BPAN, and stay tuned for more inspiring stories and informative discussions on Functional Health Radio.

Dysfunction of the supranuclear ocular motor pathways typically causes highly localizable deficits. With sophisticated neuroimaging, it is critical to better understand structure-function relationships and precisely localize pathology within the brain. In this episode, Lyell K. Jones Jr, MD, FAAN, speaks with Gregory P. Van Stavern, MD, author of the article “Supranuclear Disorders of Eye Movements” in the Continuum® April 2025 Neuro-ophthalmology issue. Dr. Jones is the editor-in-chief of Continuum: Lifelong Learning in Neurology® and is a professor of neurology at Mayo Clinic in Rochester, Minnesota. Dr. Van Stavern is the Robert C. Drews professor of ophthalmology and visual sciences at Washington University in St Louis, Missouri. Additional Resources Read the article: Internuclear and Supranuclear Disorders of Eye Movements Subscribe to Continuum®: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @LyellJ Full episode transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about earning CME, subscribing to the journal, and exclusive access to interviews not featured on the podcast. Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum: Lifelong Learning in Neurology. Today I'm interviewing Dr Gregory Van Stavern, who recently authored an article on intranuclear and supranuclear disorders of eye movements for our latest Continuum issue on neuro-ophthalmology. Dr Van Stavern is the Robert C Drews professor of ophthalmology and visual sciences at Washington University in Saint Louis. Dr Van Stavern, welcome, and thank you for joining us today. Why don't you introduce yourself to our audience? Dr Van Stavern: Hi, my name is Gregory Van Stavern. I'm a neuro-ophthalmologist located in Saint Louis, and I'm pleased to be on this show today. Dr Jones: We appreciate you being here, and obviously, any discussion of the visual system is worthwhile. The visual system is important. It's how most of us and most of our patients navigate the world. Roughly 40% of the brain---you can correct me if I'm wrong---is in some way assigned to our visual system. But it's not just about the sensory experience, right? The afferent visual processing. We also have motor systems of control that align our vision and allow us to accurately direct our vision to visual targets of interest. The circuitry is complex, which I think is intimidating to many of us. It's much easier to see a diagram of that than to describe it on a podcast. But I think this is a good opportunity for us to talk about the ocular motor exam and how it helps us localize lesions and, and better understand diagnoses for certain disorders. So, let's get right to it, Dr Van Stavern. If you had from your article, which is outstanding, a single most important message for our listeners about recognizing or treating patients with ocular motor disorders, what would that message be? Dr Van Stavern: Well, I think if we can basically zoom out a little to the big picture, I think it really emphasizes the continuing importance of the examination. History as well, but the examination. I was reading an article the other day that was essentially downplaying the importance of the physical examination in the modern era with modern imaging techniques and technology. But for neurology, and especially neuro-ophthalmology, the history and the examination should still drive clinical decision-making. And doing a careful assessment of the ocular motor system should be able to tell you exactly where the lesion is located, because it's very easy to order a brain MRI, but the MRI is, like Forrest Gump might say, it's like a box of chocolates. You never know what you're going to find. You may find a lot of things, but because you've done the history and the examination, you can see if whatever lesion is uncovered by the MRI is the lesion that explains what's going on with the patient. So even today, even with the most modern imaging techniques we have, it is still really important to know what you're looking for. And that's where the oculomotor examination can be very helpful. Dr Jones: I did not have Forrest Gump on my bingo card today, Dr Van Stavern, but that's a really good analogy, right? If you order the MRI, you don't know what you're going to get. And then- and if you don't have a really well-formed question, then sometimes you get misleading information, right?  Dr Van Stavern: Exactly. Dr Jones: We'll get into some technology here in a minute, because I think that's relevant for this discussion. I think most of our listeners are going to agree with us that the exam is important in neuro-ophthalmology, and neurology broadly. So, I think you have some sympathetic listeners there. Again, the point of the exam is to localize and then lead to a diagnosis that we can help patients with. When you think about neurologic disorders where the ocular motor exam helps you get to the right diagnosis, obviously disorders of eye movements, but sometimes it's a clue to a broader neurologic syndrome. And you have some nice discussions in your article about the ocular motor clues to Parkinson disease or to progressive supranuclear palsy. Tell us a little more about that. In your practice, which neurologic disorders do you find the ocular motor exam being most helpful? Dr Van Stavern: Well, just a very brief digression. So, I started off being an ophthalmology resident, and I do two years of ophthalmology and then switch to neurology. And during neurology residency, I was debating which subspecialty to go into, and I realized that neuro-ophthalmology touches every other subspecialty in neurology. And it goes back to the fact that the visual system is so pervasive and widely distributed throughout the brain. So, if you have a neurologic disease, there is a very good chance it is going to affect vision, maybe in a minor way or a major way. That's why careful assessment of the visual system, and particularly the oculomotor system, is really helpful for many neurologic diseases. Neuromuscular disease, obviously, myasthenia gravis and certain myopathies affect the eye movements. Neurodegenerative diseases, in particular Parkinson's disease and parkinsonian conditions, often affect the eye movements. And in particular, when you're trying to differentiate, is this classic Parkinson's disease? Or is this progressive supranuclear palsy? Is it some broad spectrum multisystem atrophy? The differences between the eye movement disorders, even allowing for the fact that there's overlap, can really help point in one direction to the other, and again, prevent unnecessary testing, unnecessary treatment, and so on. Dr Jones: Very good. And I think, to follow on a thread from that concept with patients who have movement disorders, in my practice, seeing older patients who have a little bit of restriction of vertical gaze is not that uncommon. And it's more common in patients who have idiopathic Parkinson disease. And then we use that part of the exam to help us screen patients for other neurodegenerative syndromes like progressive nuclear- supranuclear palsy. So, do you have any tips for our listeners to- how to look at, maybe, vertical gaze and say, this is maybe a normal age-related degree of change. This is something that might suggest idiopathic Parkinson disease. Or maybe something a little more progressive and sinister like progressive super nuclear palsy? Dr Van Stavern: Well, I think part of the issue- and it's harder to do this without the visual aspect. One of my colleagues always likes to say for a neurologist, the eye movement exam begins and ends with the neurology benediction, just doing the sign of the cross and checking the eye movements. And that's a good place to start. But I think it's important to remember that all you're looking at is smooth pursuit and range of eye movements, and there's much more to the oculomotor examination than that. There's other aspects of eye movement. Looking at saccades can be really helpful; in particular, classically, saccadic movements are selectively abnormal in PSP versus Parkinson's with progressive supranuclear palsy. Saccades, which are essentially rapid movements of the eyes---up and down, in this case---are going to be affected in downward gaze. So, the patient is going to have more difficulty initiating downward saccades, slower saccades, and less range of movement of saccades in downgaze. Whereas in Parkinson's, it's classically upward eye movements and upgaze. So, I think that's something you won't be able to see if you're just doing, looking at, you know, your classic, look at your eye movements, which are just assessing, smooth pursuit. Looking carefully at the eye movements during fixation can be helpful. Another aspect of many parkinsonian conditions is saccadic intrusions, where there's quick movements or saccades of the eye that are interrupting fixation. Much, much more common in PSP than in Parkinson's disease. The saccadic intrusions are what we call square-wave jerks because of what they look like. Eye movement recordings are much larger amplitude in PSP and other multisystem atrophy diseases than with Parkinson's. And none of these are perfect differentiators, but the constellation of those findings, a patient with slow downwards saccades, very large amplitude, and frequent saccadic intrusions might point you more towards this being PSP rather than Parkinson's. Dr Jones: That's a great pearl, thinking about the saccades in addition to the smooth pursuit. So, thank you for that. And you mentioned eye movement measurements. I think it's simultaneously impressive and a little scary that my phone can tell when I'm looking at it within a few degrees of visual attention. So, I imagine there are automated tools to analyze eye movement. Tell us, what's the state of the art there, and what should our listeners be aware of in terms of tools that are available and what they can and can't do? Dr Van Stavern: Well, I could tell you, I mean, I see neuro-ophthalmic patients with eye movement disorders every day and we do not have any automated tools for eye movement. We have a ton of imaging techniques for imaging the optic nerve and the retina in different ways, but we don't routinely employ eye movement recording devices. The only time we usually do that is in somebody where we suspect they have a central or peripheral vestibular disease and we send them for vestibular testing, for eye movement recordings. There is interest in using- I know, again, sort of another digression, but if you're looking at the HINTS technique, which is described in the chapter to differentiate central from peripheral disease, which is a very easy, useful way to differentiate central from peripheral or peripheral vestibular disease. And again, in the acute setting, is this a stroke or not a stroke? Is it the brain or is it the inner ear? Part of the problem is that if you're deploying this widespread, the people who are doing it may not be sufficiently good enough at doing the test to differentiate, is a positive or negative test? And that's where some people have started introducing this into the emergency room, these eye movement recording devices, to give the- using, potentially, AI and algorithms to help the emergency room physicians say, all right, this looks like a stroke, we need to admit the patient, get an MRI and so on, versus, this is vestibular neuritis or an inner ear problem, treat them symptomatically, follow up as an outpatient. That has not yet been widely employed. It's a similar way that a lot of institutions are having fundus photography and OCT devices placed in the emergency room to aid the emergency room physician for patients who present with acute vision issues. So, I think that could be the future. It probably would be something that would be AI-assisted or AI-driven. But I can tell you at least at our institution and most of the ones I know of, it is not routinely employed yet. Dr Jones: So maybe on the horizon, AI kind of facilitated tools for eye movement disorder interpretation, but it's not ready for prime time yet. Is that a fair summary? Dr Van Stavern: In my opinion, yes. Dr Jones: Good to know. This has struck me every time I've read about ocular motor anatomy and ocular motor disorders, whether they're supranuclear or intranuclear disorders. The anatomy is complex, the circuitry is very complicated. Which means I learn it and then I forget it and then I relearn it. But some of the anatomy isn't even fully understood yet. This is a very complex real estate in the brainstem. Why do you think the neurophysiology and neuroanatomy is not fully clarified yet? And is there anything on the horizon that might clarify some of this anatomy? Dr Van Stavern: The very first time I encountered this topic as an ophthalmology resident and later as a neurology resident, I just couldn't understand how anyone could really understand all of the circuitry involved. And there is a lot of circuitry that is involved in us simply having clear, single binocular vision with the afferent and efferent system working in concert. Even in arch. In my chapter, when you look at the anatomy and physiology of the smooth pursuit system or the vertical gaze pathways, there's a lot of, I'll admit it, there's a lot of hand waving and we don't completely understand it. I think a lot of it has to do with, in the old days, a lot of the anatomy was based on lesions, you know, lesion this area either experimentally or clinically. And that's how you would determine, this is what this region of the brain is responsible for. Although we've gotten more sophisticated with better imaging, with functional connectivity MRI and so on, all of those have limitations. And that's why I still don't think we completely understand all the way this information is integrated and synthesized, and, to get even more big level and esoteric, how this makes its way into our conscious mind. And that has to do with self-awareness and consciousness, which is a whole other kettle of fish. It's just really complicated. I think when I'm at least talking to other neurologists and residents, I try to keep it as simple as possible from a clinical standpoint. If you see someone with an eye movement problem, try to see if you can localize it to which level you're dealing with. Is it a muscle problem? Is it neuromuscular junction? Is it nerve? Is it nucleus? Is it supranuclear? If you can put it at even one of those two levels, you have eliminated huge territories of neurologic real estate, and that will definitely help you target and tailor your workup. So, again, you're not costing the patient in the healthcare system hundreds of thousands of dollars. Dr Jones: Great points in there. And I think, you know, if we can't get it down to the rostral interstitial nucleus of the medial longitudinal fasciculus, if we can get it to the brainstem, I think that's obviously- that's helpful in its own right. And I imagine, Dr Van Stavern, managing patients with persistent ocular motor disorders is a challenge. We take foveation for granted, right, when we can create these single cortical images. And I imagine it's important for daily function and difficult for patients who lose that ability to maintain their ocular alignment. What are some of the clinical tools that you use in your practice that our listeners should be aware of to help patients that have a persistent supranuclear disorder of ocular movement? Dr Van Stavern: Well, I think you tailor your treatment to the symptoms, and if it's directly due to underlying condition, obviously you treat the underlying condition. If they have sixth nerve palsy because of a skull base tumor, obviously you treat the skull base tumor. But from a practical standpoint, I think it depends on what the symptom is, what's causing it, and how much it's affecting their quality of life. And everyone is really different. Some patients have higher levels of tolerance for blurred vision and double vision. For things- for patients who have double vision, depending upon the underlying cause we can sometimes use prisms and glasses. Prisms are simply- a lot of people just think prism is this, like, mystical word that means a lot. It's simply just an optical device that bends light. So, it essentially bends light to allow the eyes- basically, the image to fall on the fovea in both eyes. And whether the prisms help or not is partly dependent upon how large the misalignment is. If somebody has a large degree of misalignment, you're not going to fix that with prism. The amount of prism you'd need to bend the light enough to land on the fovea in both eyes would cause so much blur and distortion that it would essentially be a glorified patch. So, for small ranges of misalignment, prisms are often very helpful, that we can paste over glasses or grind into glasses. For larger degrees of misalignment that- let's say it is due to some skull base tumor or brain stem lesion that is not going to get better, then eye muscle surgery is a very effective option. We usually like to give people a long enough period of time to make sure there's no change before proceeding with eye muscle surgery. Dr Jones: Very helpful. So, prisms will help to a limited extent with misalignment, and then surgery is always an option if it's persistent. That's a good pearl for, I think, our listeners to take away. Dr Van Stavern: And even in those circumstances, even prisms and eye muscle surgery, the goal is primarily to cause single binocular vision and primary gaze at near. Even in those cases, even with the best results, patients are still going to have double vision, eccentric gaze. For most people, that's not a big issue, but we have had a few patients… I had a couple of patients who were truck drivers who were really bothered by the fact that when they look to the left, let's say because it's a 4th nerve palsy on the right, they have double vision. I had a patient who was a golfer who was really, really unhappy with that. Most people are okay with that, but it all depends upon the individual patient and what they use their vision for. Dr Jones: That's a great point. There's not enough neurologists in the world. I know for a fact there are not enough neuro-ophthalmologists in the world, right? There's just not many people that have that dual expertise. You mentioned that you started with ophthalmology and then did neurology training. What do you think the pipeline looks like for neuro-ophthalmology? Do you see growing interest in this among trainees, or unchanged? What are your thoughts about that? Dr Van Stavern: No, that's a continuing discussion we're having within our own field about how to attract more residents into neuro-ophthalmology. And there's been a huge shift. In the past, this was primarily ophthalmology-driven. Most neuro-ophthalmologists were trained in ophthalmology initially before doing a fellowship. The last twenty years, it switched. Now there's an almost 50/50 division between neurologists and ophthalmologists, as more neurologists have become more interested. This is probably a topic more for the ophthalmology equivalent of Continuum. One of the perceptions is this is not a surgical subspecialty, so a lot of ophthalmology residents are disincentivized to pursue it. So, we have tried to change that. You can do neuro-ophthalmology and do eye muscle surgery or general ophthalmology. I think it really depends upon whether you have exposure to a neuro-ophthalmologist during your neurology residency. If you do not have any exposure to neuro-ophthalmology, this field will always seem mysterious, a huge black box, something intimidating, and something that is not appealing to a neurologist. I and most of my colleagues make sure to include neurology residents in our clinic so they at least have exposure to it. Dr Jones: That's a great point. If you never see it, it's hard to envision yourself in that practice. So, a little bit of a self-fulfilling prophecy. If you don't have neuro-ophthalmologists, it's hard to expose that practice to trainees. Dr Van Stavern: And we're also trying; I mean, we make sure to include medical students, bring them to our meetings, present research to try to get them interested in this field at a very early stage. Dr Jones: Dr Van Stavern, great discussion, very helpful. I want to thank you for joining us today. I want to thank you for not just a great podcast, but also just a wonderful article on ocular motor disorders, supranuclear and intranuclear. I learned a lot, and hopefully our listeners did too. Dr Van Stavern: Well, thanks. I really appreciate doing this. And I love Continuum. I learn something new every time I get another issue. Dr Jones: Well, thanks for reading it. And I'll tell you as the editor of Continuum, I learn a lot reading these articles. So, it's really a joy to get to read, up to the minute, cutting-edge clinical content for neurology. Again, we've been speaking with Dr Gregory Van Stavern, author of a fantastic article on intranuclear and supranuclear disorders of eye movements in Continuum's most recent issue on neuro-ophthalmology. Please check it out, and thank you to our listeners for joining today. Dr Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audioCME. Thank you for listening to Continuum Audio.

Scientists, leaders, and patients discuss the intersection of cutting-edge science and real-world impact. They explore the importance of patient perspectives in shaping medical advancements and how collaboration fuels groundbreaking research. Key scientific achievements in areas like regenerative medicine, cancer therapies, and space biology are highlighted. The group emphasizes the need for scientists to engage more with the public—through social media and media appearances—to help people understand and value the life-changing discoveries in science. Featuring: Catriona Jamieson, M.D., Ph.D. UC San Diego Sandra Dillon Patient Advocate Alexander Khalessi, M.D., M.B.A. UC San Diego Jana Stoudemire Celestial Strategy, LLC Alysson Muotri, Ph.D. UC San Diego Rebecca Moores Philanthropist and Patient Advocate Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40519]

Scientists, leaders, and patients discuss the intersection of cutting-edge science and real-world impact. They explore the importance of patient perspectives in shaping medical advancements and how collaboration fuels groundbreaking research. Key scientific achievements in areas like regenerative medicine, cancer therapies, and space biology are highlighted. The group emphasizes the need for scientists to engage more with the public—through social media and media appearances—to help people understand and value the life-changing discoveries in science. Featuring: Catriona Jamieson, M.D., Ph.D. UC San Diego Sandra Dillon Patient Advocate Alexander Khalessi, M.D., M.B.A. UC San Diego Jana Stoudemire Celestial Strategy, LLC Alysson Muotri, Ph.D. UC San Diego Rebecca Moores Philanthropist and Patient Advocate Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40519]

Scientists, leaders, and patients discuss the intersection of cutting-edge science and real-world impact. They explore the importance of patient perspectives in shaping medical advancements and how collaboration fuels groundbreaking research. Key scientific achievements in areas like regenerative medicine, cancer therapies, and space biology are highlighted. The group emphasizes the need for scientists to engage more with the public—through social media and media appearances—to help people understand and value the life-changing discoveries in science. Featuring: Catriona Jamieson, M.D., Ph.D. UC San Diego Sandra Dillon Patient Advocate Alexander Khalessi, M.D., M.B.A. UC San Diego Jana Stoudemire Celestial Strategy, LLC Alysson Muotri, Ph.D. UC San Diego Rebecca Moores Philanthropist and Patient Advocate Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40519]

Scientists, leaders, and patients discuss the intersection of cutting-edge science and real-world impact. They explore the importance of patient perspectives in shaping medical advancements and how collaboration fuels groundbreaking research. Key scientific achievements in areas like regenerative medicine, cancer therapies, and space biology are highlighted. The group emphasizes the need for scientists to engage more with the public—through social media and media appearances—to help people understand and value the life-changing discoveries in science. Featuring: Catriona Jamieson, M.D., Ph.D. UC San Diego Sandra Dillon Patient Advocate Alexander Khalessi, M.D., M.B.A. UC San Diego Jana Stoudemire Celestial Strategy, LLC Alysson Muotri, Ph.D. UC San Diego Rebecca Moores Philanthropist and Patient Advocate Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40519]

Scientists, leaders, and patients discuss the intersection of cutting-edge science and real-world impact. They explore the importance of patient perspectives in shaping medical advancements and how collaboration fuels groundbreaking research. Key scientific achievements in areas like regenerative medicine, cancer therapies, and space biology are highlighted. The group emphasizes the need for scientists to engage more with the public—through social media and media appearances—to help people understand and value the life-changing discoveries in science. Featuring: Catriona Jamieson, M.D., Ph.D. UC San Diego Sandra Dillon Patient Advocate Alexander Khalessi, M.D., M.B.A. UC San Diego Jana Stoudemire Celestial Strategy, LLC Alysson Muotri, Ph.D. UC San Diego Rebecca Moores Philanthropist and Patient Advocate Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40519]

Scientists, leaders, and patients discuss the intersection of cutting-edge science and real-world impact. They explore the importance of patient perspectives in shaping medical advancements and how collaboration fuels groundbreaking research. Key scientific achievements in areas like regenerative medicine, cancer therapies, and space biology are highlighted. The group emphasizes the need for scientists to engage more with the public—through social media and media appearances—to help people understand and value the life-changing discoveries in science. Featuring: Catriona Jamieson, M.D., Ph.D. UC San Diego Sandra Dillon Patient Advocate Alexander Khalessi, M.D., M.B.A. UC San Diego Jana Stoudemire Celestial Strategy, LLC Alysson Muotri, Ph.D. UC San Diego Rebecca Moores Philanthropist and Patient Advocate Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40519]

Scientists, leaders, and patients discuss the intersection of cutting-edge science and real-world impact. They explore the importance of patient perspectives in shaping medical advancements and how collaboration fuels groundbreaking research. Key scientific achievements in areas like regenerative medicine, cancer therapies, and space biology are highlighted. The group emphasizes the need for scientists to engage more with the public—through social media and media appearances—to help people understand and value the life-changing discoveries in science. Featuring: Catriona Jamieson, M.D., Ph.D. UC San Diego Sandra Dillon Patient Advocate Alexander Khalessi, M.D., M.B.A. UC San Diego Jana Stoudemire Celestial Strategy, LLC Alysson Muotri, Ph.D. UC San Diego Rebecca Moores Philanthropist and Patient Advocate Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40519]

Scientists, leaders, and patients discuss the intersection of cutting-edge science and real-world impact. They explore the importance of patient perspectives in shaping medical advancements and how collaboration fuels groundbreaking research. Key scientific achievements in areas like regenerative medicine, cancer therapies, and space biology are highlighted. The group emphasizes the need for scientists to engage more with the public—through social media and media appearances—to help people understand and value the life-changing discoveries in science. Featuring: Catriona Jamieson, M.D., Ph.D. UC San Diego Sandra Dillon Patient Advocate Alexander Khalessi, M.D., M.B.A. UC San Diego Jana Stoudemire Celestial Strategy, LLC Alysson Muotri, Ph.D. UC San Diego Rebecca Moores Philanthropist and Patient Advocate Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40519]

Scientists, leaders, and patients discuss the intersection of cutting-edge science and real-world impact. They explore the importance of patient perspectives in shaping medical advancements and how collaboration fuels groundbreaking research. Key scientific achievements in areas like regenerative medicine, cancer therapies, and space biology are highlighted. The group emphasizes the need for scientists to engage more with the public—through social media and media appearances—to help people understand and value the life-changing discoveries in science. Featuring: Catriona Jamieson, M.D., Ph.D. UC San Diego Sandra Dillon Patient Advocate Alexander Khalessi, M.D., M.B.A. UC San Diego Jana Stoudemire Celestial Strategy, LLC Alysson Muotri, Ph.D. UC San Diego Rebecca Moores Philanthropist and Patient Advocate Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40519]

Scientists, leaders, and patients discuss the intersection of cutting-edge science and real-world impact. They explore the importance of patient perspectives in shaping medical advancements and how collaboration fuels groundbreaking research. Key scientific achievements in areas like regenerative medicine, cancer therapies, and space biology are highlighted. The group emphasizes the need for scientists to engage more with the public—through social media and media appearances—to help people understand and value the life-changing discoveries in science. Featuring: Catriona Jamieson, M.D., Ph.D. UC San Diego Sandra Dillon Patient Advocate Alexander Khalessi, M.D., M.B.A. UC San Diego Jana Stoudemire Celestial Strategy, LLC Alysson Muotri, Ph.D. UC San Diego Rebecca Moores Philanthropist and Patient Advocate Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40519]

Send us a textThis week on The Less Stressed Life, we're talking about reversing cognitive decline and optimizing brain health with Dr. Heather Sandison, author of Reversing Alzheimer's. As a naturopathic doctor and founder of the first memory recovery residential program, Dr. Sandison shares the six root causes of neurodegeneration—and how you can bring the brain back into balance at any age.We're talking about reversing Alzheimer's and neurodegenerative conditions (although it is so much more). From toxins to stress to nutrition, this empowering episode offers real hope and practical tools for preventing and even reversing memory loss. Whether you're supporting a loved one or thinking ahead for your own brain, this is one conversation you don't want to miss.Dr. Sandison's free Keto Diet Guide can be downloaded at: https://www.drheathersandison.com/In that website people can also watch all her content and read her blogKEY TAKEAWAYS:The six root causes of cognitive decline (and how to assess them)How toxins and stress quietly sabotage brain healthWhat your ApoE4 gene does—and doesn't—mean for your futureSigns of early cognitive decline most people missWhat Dr. Sandison's clinical trial revealed about reversing Alzheimer'sABOUT GUEST:Dr. Heather Sandison is the NYT bestselling author of “Reversing Alzheimer's The New Toolkit to Improve Cognition and Protect Brain Health”. She is a renowned naturopathic doctor specializing in neurocognitive medicine and the founder of Solcere Health Clinic, San Diego's premier brain optimization clinic, and Marama, a residential program turning memory care into memory recovery. She has dedicated her career to supporting those suffering with dementia and is the primary author of peer reviewed research published in the Journal of Alzheimer's Disease. She is excited to shatter common misconceptions about Alzheimer's and share what she has learned about keeping your brain sharp at any age.WHERE TO FIND:Website: https://www.drheathersandison.com/Instagram: https://www.instagram.com/dr.heathersandison/WHERE TO FIND CHRISTA:Website: https://www.christabiegler.com/Instagram: @anti.inflammatory.nutritionistPodcast Instagram: @lessstressedlifeYouTube: https://www.youtube.com/@lessstressedlifeSPONSOR:Thanks to Jigsaw Health for sponsoring this episode! Struggling with dry, cracked hands? Try their Alaska Cod Liver Oil for omega-3s + vitamins A & D to support skin and immune health. Use code LESSSTRESSED10 at JigsawHealth.com for 10% off—unlimited use!WORK WITH CHRISTA: I've streamlined my proven method to help you get to the REAL root of eczema and food sensitivities—without the overwhelm. Join the program at christabiegler.com before doors close!

Tuesday, April 8 -  Host Doug Stephan and Dr. Ken Kronhaus of Lake Cardiology (352-735-1400) cover a number of topics affecting our health. First up, Doug and Dr. Ken start with some good news from the world of medicine with a simple smell test for early detection of Alzheimer's in an effort to treat the neurodegenerative disease early. Then, the conversation shifts to a focus between the connection between heart problems and brain diseases, evidence of animals and degenerative brain diseases, the FDA approves the first home-based nonprescription diagnostic test for certain STDs for women, sugar substitutes and why they aren't always a better alternative, children of obese mothers are more likely to become an obese adult, and the differences between the diabetes and weight loss drugs. Questioning why it's so difficult to find a doctor, and why there's such a long weight to get in with your medical team, the latest information on the Avian Flu, and changes in Medicaid affecting your wallet. Doug and Dr. Ken discuss that, too. Website: GoodDayHealthShow.com Social Media: @GoodDayNetworks

Spinocerebellar ataxia includes a group of rare, genetic, neurodegenerative disorders. People with the condition suffer from the loss of balance, coordination, and muscle control. As the condition progresses, people can lose the ability to walk and speak. There is no approved treatment for SCA, but Biohaven has applied to the U.S. Food and Drug Administration to begin marketing its experimental therapy troriluzole, which can normalize levels of glutamate, a key neurotransmitter implicated in the disease. We spoke to Melissa Beiner, senior medical director at Biohaven, about spinocerebellar ataxia, the company's therapy under review at the FDA to treat the condition, and why it may have the potential to benefit a number of other neurological conditions as well.

Join us for this conversation with Dr. Carolyn Dean, a renowned expert in the fields of minerals and nutrients, to discuss their crucial role in mental health. Dr. Dean, the author of The Magnesium Miracle, shares valuable insights on how essential minerals--especially magnesium--play a pivotal role in brain function, mood regulation, and overall mental well-being. Throughout the conversation, she highlights the impact of nutrient deficiencies on mental health conditions like anxiety, depression, ADHD, and stress. The discussion also delves into how bioavailable forms of minerals can enhance absorption and contribute to better mental clarity, emotional balance, and resilience. She offers practical advice for supplementing with these vital nutrients and discusses the importance of maintaining a balanced diet for optimal brain health. If you're interested in improving your mental health through nutrition and supplementation, this episode is packed with actionable tips and expert guidance!Dr. Carolyn Dean! She's a leading expert in integrative health, with over 35 books and publications to her name, including her latest, The Complete Guide to Mental Health. Dr. Dean's expertise goes beyond traditional medicine, focusing on nutrition, stress management, and holistic healing. She's also the founder of RnA ReSet, a company dedicated to creating nutrient-based products for optimal wellness.SHOW NOTES:0:39 Welcome to the show!6:13 Dr. Carolyn Dean's Bio6:39 Welcome her to the podcast!8:08 Renee's definition of mental wellness8:51 Carolyn's experience during Covid10:18 New German Medicine12:23 Addressing sleep problems 13:45 Essentials for mental health14:57 Magnesium & Mitochondria17:30 Neurodegenerative diseases, ATP & Magnesium18:20 Heavy metal toxicity20:39 Food-based vs Synthetic supplements23:19 How to build mental wellness25:14 Hydration essentials29:34 Nano-Pico minerals31:55 Methylation36:08 Co-factors for optimal methylation38:33 Anxiety, OCD & ADHD40:00 Methylation issues & mineral insufficiencies43:04 Non-laxative magnesiums46:25 Children w/ ADHD51:25 Zinc & Copper balancing56:44 RNA Reset59:25 Her final piece of advice1:01:15 Thanks for tuning in!RESOURCES:Websites: DrCarolynDean.comRNAReset Minerals - code: BIOHACKERBABES10Book: Complete Guide to Mental HealthIG: @drcarolyndeanYouTubeOur Sponsors:* Check out Puori: https://puori.com/BIOHACKERBABESSupport this podcast at — https://redcircle.com/biohacker-babes-podcast/donationsAdvertising Inquiries: https://redcircle.com/brands

On this episode of The Manchester Living Podcast, host Brian Levy sits down with Alyce Levy and Dr. Bradley McDaniels for a powerful and inspiring conversation about living with neurodegenerative conditions such as Multiple Sclerosis (MS) and Parkinson's Disease. Alyce opens up about her personal journey with MS—from the onset of symptoms to discovering purpose and building a supportive community. Dr. McDaniels offers expert perspective on the critical role of social connection, mental health, and holistic wellness in navigating life with these conditions.http://www.ManchesterLivingPodcast.com

When we think about improving our health, our brain is often overlooked, but it shouldn't be. Neurodegenerative illnesses are among the leading causes of death globally. Even more pressing, a sick, inflamed, or imbalanced brain can immediately diminish your quality of life. This week, we're joined by a neurologist and author whose work highlights lifestyle interventions that boost brain health. Listen and learn: What the Default Mode Network is and its role in your brain Factors that contribute to migraine and why management might be the key How mindfulness practices can support long term brain health Simple ways to start improving your brain health today LINK www.drsuiwongmd.com ABOUT OUR GUEST Dr. Sui H. Wong is a neurologist and neuro-ophthalmologist based in London, UK. She has authored a number of books including Sweet Spot for Brain Health, Sleep Better to Thrive, and Break Free From Migraines Naturally.  Like the Show? Leave us a review Check out our YouTube channel

Welcome to an episode where we explore the cutting-edge world of photobiomodulation (PBM) and its potential to transform the landscape of neurodegenerative disease treatment. This episode features an in-depth interview with Liam Pingree, CEO of Neuronic, we dive into the science behind PBM and the innovative Neuradiant 1070 device. Building on our discussion from last year, we'll uncover how this non-invasive therapy leverages red and near-infrared light to enhance brain health, with a focus on conditions like Alzheimer's and Parkinson's. Photobiomodulation, often called low-level laser or red light therapy, is gaining traction as a promising approach to tackle the mitochondrial dysfunction and inflammation that drive neurodegenerative diseases. Today, we'll hear from Liam about how the Neuradiant 1070, with its unique 1070 nm wavelength, aims to penetrate deeper into the brain, offering hope for symptom relief and possibly slowing disease progression. We'll also spotlight the contributions of key researchers, including Professor Paul Chazot, whose work on neuroinflammation ties into this field, alongside pioneers like Michael R. Hamblin driving PBM research forward. Join us as we break down the device's features, clinical applications, and real-world user experiences, all while peering into the future of PBM as a potential standard in brain health care. Whether you're a science enthusiast, a caregiver, or someone curious about innovative therapies, this episode offers a compelling look at how light might just shine a new path forward for neurodegenerative challenges. Let's dive in! What You'll Learn in This Episode: The Science of Photobiomodulation (PBM): Understand how PBM uses red and near-infrared light to boost mitochondrial function, reduce inflammation, and promote neurogenesis, with insights into its relevance for Alzheimer's and Parkinson's. The Neuradiant 1070 Device: Explore the specifics of this home-use PBM device, including the significance of its 1070 nm wavelength for brain penetration and its quadrant control system for targeted treatment. Key Research Contributions: Learn about the work of leading researchers like Michael R. Hamblin, John Mitrofanis, and Paul Chazot, whose studies on PBM and neuroinflammation are shaping the field. Clinical Applications and Future Vision: Discover how the Neuradiant 1070 is being used for neurodegenerative conditions, supported by emerging clinical trials, and hear Liam Pingree's vision for PBM's role in prevention and treatment by 2027.

Have new breakthroughs been made in treating Parkinson's Disease? Through new therapeutic techniques, promising results have been shown. Listen up to learn: Early parkinsonian symptoms The targets of current research The function of L-Dopa Dr. Anumantha Kanthasamy, the Director of the Center for Brain Science, shares his research and work developing new therapies and detection methods for Parkinson's Disease. Parkinson's Disease and other neurodegenerative diseases have long plagued folks around the globe. Unfortunately, despite the prevalence of these conditions, there has been little progress in treating or reversing the associated symptoms. One of the most promising sites of progress in treating such diseases has been the gut biome. Since the gut biome is one of the most significant influences on the rest of the body, learning how to influence it can help us better regulate the brain. Visit https://vet.uga.edu/person/anumantha-kanthasamy/ to learn more. Episode also available on Apple Podcasts: http://apple.co/30PvU9C Boost Your Brainpower with 15% OFF!  Fuel your mind with BrainSupreme Supplements and unlock your full potential. Get 15% OFF your order now using this exclusive link: brainsupreme.co/discount/findinggenius Hurry—your brain deserves the best!

David Haase, MD, FABFM, DAIOM, IFM-MD, CNS, QIA, joins Integrative Practitioner Content Specialist Avery St. Onge to discuss how Habitat Optimizing Plasma Exchange (HOPE) can modify the progression of neurodegenerative diseases such as Alzheimer's and dementia. This episode is brought to you by the Integrative Healthcare Symposium. Register for the Symposium and receive 15% off with promo code IP2025PODCAST: https://xpressreg.net/register/ihsy0225/landing.php?sc=IP2025PODCAST Learn more about the event by visiting the Symposium website: www.ihsymposium.com Contact the Integrative Healthcare Symposium team: info@ihsymposium.com Find us at integrativepractitioner.com or e-mail us at IPEditor@divcom.com. Theme music: "Upbeat Party" by Scott Holmes via freemusicarchive.org, "Carefree" by Kevin Mcleod via incompetech.com, and “Relaxing Light Background” by AudioCoffee. About the Expert David Haase, MD is a highly curious physician, holding a medical degree from Vanderbilt University School of Medicine and completing his residency and practice at the esteemed Mayo Clinic in Rochester, Minnesota. He also holds a Certification: Qualification in Apheresis (QIA). He is distinguished by double board certification in Family Medicine and Integrative Holistic Medicine and currently serves as Lead Faculty for the Institute for Functional Medicine. Dr. Haase's influence extends globally, having trained over 10,000 physicians worldwide in his innovative approach to Alzheimer's, dementia, and complex chronic illnesses.

OCD, or Obsessive Compulsive Disorder, is a debilitating condition that involves intrusive thoughts and time-consuming, repetitive behaviors. It impacts 80 million worldwide, 2-4% of the US population or 1 in 100 people here in the US.It can be difficult to overstate the suffering caused by OCD, not only for those with this condition but also for their family members. In addition to the distress caused by the obsessional thoughts and compulsions, there can be shame and loss - loss of more meaningful, purposeful, or pleasant thoughts and behaviors. and loss of time connecting with others or engaging in purposeful or enjoyable activities.Other conditions associated with obsessive-compulsive disorder include:* Body dysmorphic disorder* Skin picking* Trichotillomania (hair pulling)* Hoarding* Hypochondria* Olfactory reference syndrome (an irrational feeling or belief that one emits a foul smell and often attempts to remove the odor).It´s not unusual for someone with OCD to have other conditions, such as:* Other forms of anxiety* Depression* ADHD* Autism spectrum disorder* Eating disorders* TourettesResearch suggests that having OCD raises one´s vulnerability to developing dementia. Many other brain conditions, however, also appear to increase this vulnerability similarly.Treatment ChallengesOCD is particularly challenging to treat. Of those with OCD, 60% do not respond to typical therapies (often medication in combination with psychotherapy involving gradual exposure to that which is being avoided). Typical medications include:* SSRI´s (Selective Serotonin Reuptake Inhibitors) -e.g., sertraline, fluoxetine, fluvoxamine, citalopram, paroxetine* Tricyclic antidepressant - clomipramine* SNRI - (Serotonin and Norepinephrine Reuptake Inhibitor) - venlafaxine* Atypical antipsychotic medications are sometimes addedMedication is combined with CBT (Cognitive Behavioral Therapy), which involves exposure and response prevention, or CBT is used alone.As you can see, most medication approaches aim to increase serotonin activity. Serotonin, however, is just one of the neurotransmitters involved. What has become increasingly clear from the research is that OCD involves abnormal activity at the NMDA receptor - a glutamate receptor.NMDA & GlutamateThe NMDA receptor is found throughout the brain. Glutamate, the primary excitatory neurotransmitter in the central nervous system, binds to the NMDA receptor. NMDA and glutamate are involved in synaptic plasticity (creating neuronal connections), learning, memory, and motor function.The synapse is the space between communicating neurons. Presynaptic neurons release glutamate, which binds to the NMDA receptor on postsynaptic neurons. This results in a cascade of signaling events that lead to “neuronal excitation.” The problem arises when this receptor has too much (or too little) activity. In the case of OCD, there is too much activity.Implications* Dysregulation at the NMDA receptor appears to play a role in OCD, depression, PTSD, schizophrenia, bipolar disorder, and substance use disorders.* Weak memory extinction can result from high activity at the NMDA receptor. While memory is a good thing, we can have problems with too much memory - or rather, problems putting our memories aside. This can look like thoughts getting stuck, for example:* Intrusive thoughts in OCD* Flashbacks in PTSD* Delusions in psychotic disorders* Cravings in addiction.* Neurodegenerative disorders, such as Alzheimer's, Parkinson's, and ALS, have also been linked to NMDA receptor malfunction.Methylation & NMDAThose who are undermethylated, especially those with OCD or addictions, have high activity at the NMDA receptor. To remind you, undermethylation is a biochemical process with many functions, including the breakdown of histamine, support of detoxification, and support of serotonin activity. When someone is undermethylated, they can tend to have allergies (from high histamine), be perfectionistic, competitive, strong-willed, have obsessive-compulsive tendencies, be ritualistic, have dietary inflexibility, and have high accomplishment or have family members with high accomplishment. Undermethylation can contribute to the low serotonin activity seen in OCD. Simply addressing undermethylation, like merely addressing serotonin, will only bring partial benefit. To address undermethylation, those of us trained by the Walsh Research Institute, use SAMe and/or methionine, B12, B6, magnesium, and antioxidants. We address this before starting methylation treatment for those with high homocysteine. But how can we also decrease activity at the NMDA receptor?Blocking NMDA & Normalizing Glutamate ActivityEsketamine or Ketamine, which has been getting much attention in recent years, can impact the brain in various ways; however, its primary mechanism is as an NMDA blocker or antagonist. For some, it can serve as a rapid-acting and highly effective antidepressant. It can also decrease OCD symptoms. Other NMDA-blocking drugs include memantine and dextromethorphan (combined with bupropion). Lamotrigine can decrease glutamate release and has been used as an adjunct medication for OCD.Nutrients, however, play an important role in the NMDA receptor. NAC or N-acetyl cysteine is a precursor to glutathione and, thus, an antioxidant. It is also anti-inflammatory and a binder for a particular toxin made by candida and mold. But, it is also a potent NMDA antagonist (decreases activity at NMDA) and has been shown to reduce obsessions and compulsions of OCD. It has also been studied in alcoholism, opiate addiction, cocaine abuse, gambling disorder, shopping disorder, cigarette addiction, and trichotillomania. It has been used by itself and as an adjunct to medication therapy. NAC has become part of the Walsh undermethylation nutrient protocols for those with OCD and/or addiction.Zinc also plays an important role in regulating functioning at the NMDA receptor. The Walsh Research Institute found that 90% of those with brain symptoms had relatively low zinc. Dosing of zinc is determined after testing plasma zinc levels using a narrow range (the Walsh/Pheiffer range differs from typical lab ranges). Zinc is checked in conjunction with copper. Zinc has been found to improve treatment response in those with OCD treated with SSRIs. Zinc can be depleted because of very high oxidative stress and/or high pyrroles, which also cause low B6. Because B6 is needed to make serotonin, pyrroles are also important to address if elevated.Inositol is a nutrient involved in the serotonin and glutamate signaling systems. It, too, is beneficial for OCD symptoms; however, it can require very high doses.The challenge of research, as you can see, is that these approaches are all looked at in isolation, as opposed to, for example, addressing undermethylation, optimizing zinc, decreasing activity at the NMDA and addressing sources of oxidative stress.Candida & MoldAside from undermethylation, low serotonin activity, and high activity at the NMDA receptor, those with OCD appear to have high oxidative stress, as is the case with most brain-related conditions. One of the more common sources of oxidative stress I see in my practice is candida overgrowth in the GI tract, which often follows antibiotic exposure and /or mold toxicity due to water damage causing seen or unseen toxic mold. Because mold and candida (yeast) thrive on sugar and a high-carb diet, symptoms can fluctuate with sugar or carb intake. How might candida and mold intersect with the NMDA receptor? Mold and yeast can contribute to high histamine states. Histamine can increase activity at the NMDA receptor. EstrogenFor women and teen girls that I see with OCD, there is often a fluctuation in their OCD symptoms with their cycle. Typically, their symptoms worsen during the times of the month when estrogen is the highest. This may be because estrogen can increase activity at the NMDA receptor.PANDAS & PANSWhen a child has an abrupt onset of OCD symptoms, PANDAS and PANS should be considered.* PANDAS = Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections* PANS = Pediatric Acute-Onset Neuropsychiatric SyndromePANDAS and PANS are autoimmune conditions, meaning the immune system is acting on the body, in this case, a part of the brain called the basal ganglia, that involves an acute onset of OCD symptoms. Other symptoms can include restricted eating, mood symptoms, regression in academic or social skills, and motor tics. While triggers are often viral, bacterial (strep in the case of PANDAS), candida,or other microbial source, what is underlying the dysregulated immune response to such microbes, in my experience, is mold toxicity. SummaryBecause OCD can be difficult to treat, my hope in sharing this information is to raise awareness that effective OCD treatments can require a multifaceted approach that includes:* addressing methylation (and high pyrroles if present) to improve serotonin activity* decreasing activity at the NMDA receptor* by optimizing zinc* using supplements or medication* addressing sources of inflammation and high histamine* address sources of oxidative stress - trauma, stress, toxins, inflammation If you find this information helpful and would like to help me get this out into the world, please consider sharing:As always, I welcome your comments, questions, and experience.Until next time,CourtneyP.S. To learn more about non-patient consultations, treatment, and monthly mentorship groups, please visit my website at:CourtneySnyderMD.comMedical Disclaimer:This newsletter and podcast episode is for educational purposes and not intended or implied to be a substitute for professional medical advice, diagnosis, or treatment for yourself or others, including but not limited to patients you are treating (if you are a practitioner). Consult your physician for any medical issues that you may be having. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit courtneysnydermd.substack.com/subscribe

Fri, 24 Jan 2025 00:00:00 +0000 https://seesee.podigee.io/s3e12-john-cryan f9d417dd4b9c1419db8383f62238f1f5 In this episode, we embark on a fascinating journey to explore one of the most groundbreaking areas of science - the gut-brain axis! Leading the way is none other than world-renowned neuroscientist Professor John Cryan of University College Cork, whose pioneering work has helped uncovered the powerful link between the gut microbiome and mental health and behaviour. Co-hosted by one of Europe's leading neurosurgeons, Peter Vajkoczy, this is one episode you won't want to miss. So, sit back and buckle up as we navigate the neural pathways that connect our gut to our brain, and discover how this connection plays a critical role in a wide range of conditions, from mental disorders to degenerative diseases. We'll delve into Professor Cryan's cutting-edge research, exploring the diseases his team in Cork are targeting and the innovative delivery systems they're developing to make genetic changes in the brain. You'll also hear about the forces that shape our microbiota throughout our lives, from the importance of vaginal birth and breast milk to the relationship between stress, dementia and depression, and the impact of diet on social behaviour, cognitive decline and aging, and mental health. We'll also explore the exciting new field of psychobiotics, which Cryan covers in his bestselling book, “The Psychobiotic Revolution: Mood, Food and the New Science of the Gut-Brain Connection”. Prepare to be amazed by the potential future treatments for neurological and mental health conditions through the lens of microbiota and neuroscience. Join us for an unforgettable episode as microbes and neurons bring us closer to understanding a shared universe of the gut and the brain! *Professor John F. Cryan is Vice-President for Research and Innovation at University College Cork (UCC), Professor in the Department of Anatomy and Neuroscience, and Principal Investigator at the APC Microbiome Ireland Institute. His pioneering research concentrates on the gut-brain axis and the impact of gut microbes on stress, psychiatric and immune disorders, as well as their influence on mental health. He is a leading figure in this field, with numerous influential publications and significant contributions to scientific research and public understanding of the microbiome. He has published over 600 peer-reviewed articles and has served as co-editor for several books. Additionally, he currently serves as Editor-in-Chief of Neuropharmacology and Neurobiology of Stress, and is a member of the editorial boards of 15 other scientific journals. **This episode is cohosted by Prof. Peter Vajcokzy. He has been Head of Neurosurgery at Charité-Universitätsmedizin in Berlin since 2007. He leads 5,000 brain surgeries a year, 800 of which he performs. He is a full professor at Charité and an associate professor at Heidelberg. He treats cerebrovascular disorders, brain tumours, skull base tumours and performs minimally invasive spine and peripheral surgery. He also performs functional neurosurgery and pain management procedures. His research focuses on brain cancer and the mechanisms of brain tumours. He also studies the monitoring of neocortically ill patients after vessel occlusion. https://publish.ucc.ie/researchprofiles/C003/jcryan Social Media: John F. Cryan (@jfcryan) · X https://scholar.google.com/citations?user=3SiQStcAAAAJ&hl=en https://www.amazon.com/Books-John-F-Cryan/s?rh=n%3A283155%2Cp_27%3AJohn+F.+Cryan TEDMED Food for thought: How gut microbes change your mind https://www.youtube.com/watch?v=kMVxbnfSP-Q Feed Your Microbes - Nurture Your Mind | John Cryan | TEDxHa'pennyBridge https://www.youtube.com/watch?v=vKxomLM7SVc NETFLIX Documentary: “Hack your Health” featuring Prof. John Cryan https://www.netflix.com/tudum/articles/hack-your-health-secrets-of-your-gut-release-date-trailer-news Grandmaternal stress and during pregnancy and DNA Germany/ Brazil and Sweden) (Paper published in 2017 Serpeloni F, Radtke K, de Assis SG, Henning F, Nätt D, Elbert T. Grandmaternal stress during pregnancy and DNA methylation of the third generation: an epigenome-wide association study. Transl Psychiatry. 2017 Aug 15;7(8):e1202. doi: 10.1038/tp.2017.153. PMID: 28809857; PMCID: PMC5611722. https://pubmed.ncbi.nlm.nih.gov/28809857/ 3 12 full no Gut-brain axis,Gut Microbiome,Microbiome,Mental health,Neuroscience,Neurobiology,Gut-brain connection,Psychobiotics,Neurodegenerative diseases,Microbiota Dr. Cecilia Ponce Rivera

The benefits of exercise for people with Parkinson's are well known, but if you're struggling to stick to your New Year's resolution to be more active, this episode should give you all the motivation you need! Ledia Alushi Agley's doctoral research at the University of Cambridge, involving more than four hundred participants, saw her co-design a physical health programme for those newly diagnosed with Parkinson's. She shares with us some of the fascinating findings of her study. which also explores current clinical practice in relation to exercise, and the views of healthcare professionals.

Recent progress in neurogenetics and molecular pathology has improved our understanding of the complex pathogenetic changes associated with neurodegenerative dementias. In this episode, Katie Grouse, MD, FAAN, speaks with Sonja W. Scholz, MD, PhD, FAAN, an author of the article “Genetics and Neuropathology of Neurodegenerative Dementias,” in the Continuum® December 2024 Dementia issue. Dr. Grouse is a Continuum® Audio interviewer and a clinical assistant professor at the University of California San Francisco in San Francisco, California. Dr. Scholz is a senior investigator at the National Institutes of Health in Bethesda, Maryland and an adjunct professor of neurology at Johns Hopkins University in Baltimore, Maryland. Additional Resources Read the article: Genetics and Neuropathology of Neurodegenerative Dementias Subscribe to Continuum: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Full episode transcript available here:  Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum, the premier topic-based neurology clinical review and CME journal from the American Academy of Neurology. Thank you for joining us on Continuum Audio, which features conversations with Continuum's guest editors and authors who are the leading experts in their fields. Subscribers to the Continuum journal can read the full article or listen to verbatim recordings of the article and have access to exclusive interviews not featured on the podcast. Please visit the link in the episode notes for more information on the article, subscribing to the journal, and how to get CME. Dr Grouse: This is Dr Katie Grouse. Today I'm interviewing Dr Sonia Scholz about her article on genetics and neuropathy of neurodegenerative dementias, which appears in the December 2024 Continuum issue on dementia. Welcome to the podcast, and please introduce yourself to our audience.  Dr Scholz: Thank you so much for inviting me. My name is Sonia Scholz. I'm a neurologist working at the National Institutes of Health. My main focus of research and clinical work are neurodegenerative diseases, and I have a particular interest in using modern genomic tools to understand these diseases and potentially leverage it for new translational applications. Dr Grouse: Sonia, we're really excited to have you today and thanks for joining us.  Dr Scholz: I'm pleased to be here.  Dr Grouse: I'd like to start by asking what you think is the most important message or takeaway point from your article? Dr Scholz: So, this is an article that really captures a very broad and exciting field. So, one thing I wanted to really highlight is that there's a lot of heterogeneity, clinical, pathological, molecular heterogeneity in age-related neurodegenerative dementia syndromes. Our article was really aimed at providing a bird's eye view of the pertinent pathological characteristics, but also important genetic advances and insights and how we can leverage that, particularly in the new physician medicine era, hopefully come up with better treatments and better ways to counsel our patients.  Dr Grouse: What do you think is the most challenging aspect of understanding the genetics and neuropathologic basis of neurodegenerative dementias?  Dr. Scholz: That's a good question. There're many big and challenging questions, but I think one of the things we struggle the most with is really the heterogeneity. I see patients with one and the same Mendelian form of dementia. One patient is in their forties another patient is in their eighties, and the clinical manifestations can be very different from one patient to another. There's a lot of heterogeneity, also, on the pathological level. Not every patient has exactly the same distribution. And so, we're starting to slowly define what the underlying causes are, but it's still quite baffling and quite challenging to put them together and understand them. Dr Grouse: Do you feel that the genome-wide association studies has helped our understanding of these diseases, specifically the heterogeneity? And if so how?  Dr Scholz: That's a great question, but you're talking to a geneticist here. And I definitely would say genome-wide association studies have helped us a lot in identifying what the underlying disease pathways are and what the relationships between neurodegenerative disease entities are. It really also gave us a better understanding of apparently sporadic diseases where genetic factors are still playing a role. And we can leverage that type of knowledge increasingly to highlight high-risk groups, but also, we can increasingly use it to stratify patients for clinical trials, for example. And that's really exciting and there's still a lot of knowledge that we have to garner very quickly, especially in the non-Alzheimer dementia space.  Dr Grouse: You've mentioned, of course, the heterogeneity and these syndromes. And in your article, you go into a lot of the issue of the significant crossover between the genetic links and the neuropathological findings for the various types of neurodegenerative dementias. Do you think that this crossover has been more of a help or a hindrance in better understanding these diseases? Dr Scholz: Yeah, it can be a little bit, you know, challenging to wrap one 's mind around it. But by and large, I think it's actually good news because it highlights that there is a shared biology between many of the neurodegenerative disease entities. And by figuring out which the pathways are that are very often involved, we can prioritize certain targets for therapy development. But we can also be smarter about how we developed treatments. We could repurpose a drug that has been developed for Alzheimer's disease very easily for Lewy body dementia because we increasingly understand the overlap. And we can also leverage new clinical trials design, like basket trials. This is something that has been really transformative in the oncology sphere and now, increasingly, neurodegeneration. We're trying to apply that kind of thinking as well to our patient populations. Dr Grouse: What do you think our listeners will find to be most surprising when they read the article? Dr Scholz: We often present these diseases in our textbooks as these black-and-white entities, but the reality is that there's a lot of overlap. And we also see that co-pathologies are actually the norm and not the exception, and a lot of the molecular risk factors are shared. It's not really surprising. And I think that overlap and crosstalk between the various diseases is something that's a little bit strange to think about, but it actually makes increasingly sense now that we see the genetic risk profiles coming up. Dr Grouse: In reading your article, I was really struck by how many, or how much the prior studies have been lacking in inclusion of different ethno-racial backgrounds in the patients who've been studied. How can this be improved going forward?  Dr Scholz: Yeah, thank you. That's a really important and crucial question, and I think it really takes the collective effort of everybody in the healthcare research community to improve upon that. We need to talk to our patients about genetic testing, about brain donation programs, about referrals to clinical trials, and don't feel shy about reaching out to our colleagues and academic centers, even if you don't have the resources in a smaller institution. We also not only need to engage with the communities, we also need to build up a healthcare research community that has representatives from these various communities. So, it's really a collective effort that we build up and are proactive about building a more equitable healthcare system and research system that works for all of us and that really is going to provide us with the precision medicines that work for everybody. Dr Grouse: What do you think is the biggest debate or controversy related to the genetics and neuropathology of neurodegenerative dementias?  Dr Scholz: Yeah, there are loads of interesting debates, but I think in my field, in particular in the genetics is what to do with risk variance. What is it that I actually communicate to the patient? Obviously, I can learn a lot on the bench and I think I can use a lot of the genetic risk factors for molecular modeling, etc. But to which extent should I share that information? Because genetic information is something that we cannot alter and many of the risk factors are actually mild, that they may never result in disease. And so, communicating risk with patients is something that's very challenging and we used to just steer away from it. But now the discussion is starting to shift a little bit. You know, nowadays we are starting to offer, for example, testing for the APOE4 allele in individuals who are considering antiamyloid therapies. And this really, this is precision medicine in his earliest days because it allows us to stratify patients into those that are high-risk versus low-risk and those that need more frequent follow-up or may be advised not to pursue this treatment. And we're probably going to see more of those discussions and the ethics around it. And it's even harder in an aged population where you know, you may never manifest any of the symptoms despite carrying a lot of these risk deals. Dr Grouse: You mentioned, you know, that testing, APOE4 testing for certain populations when deciding to do the antiamyloid immunotherapies. Apart from that, which I think is a really good example of where genetic testing makes sense, what other scenarios do you think it makes sense at this point in time to recommend genetic testing for symptomatic patients who are concerned about neurodegenerative dementias? Dr Scholz: Yeah. So, I usually have a very frank discussion with patients in whom I suspect the genetic etiology. So those are individuals who have a strong family history, individuals from very early onset of the disease where genetic testing may allow us to establish a molecular diagnosis, individualize and refine our counseling, and potentially get them into targeted clinical trials that may be suitable for that. Those are always very nuanced discussions, but I usually start with those high-risk individuals. Increasingly patients are, even with the apparently sporadic forms, are asking me about it. And then I have a frank discussions about the pros and cons and offer it to the patients who really would like to pursue it.  Dr Grouse: That makes a lot of sense. What about in the case of patients who are asymptomatic but might have high risks because of, well, family members with certain types of neurodegenerative dementias? When would it make sense, if ever, to do genetic testing for them? Dr Scholz: Yeah, that's a that's a tough situation, to be honest. By and large, I would say I would like to understand what the motivation is to learn about the genetic status. If the motivation is something like family planning, future care planning, etc, then it may be a reasonable thing. But I also want to make it very clear upfront that knowing a genetic status, at least aside from APOE status, at least for now, doesn't actually change the clinical management. And I want to make sure patients understand if they are trying to lower their risk, knowing that genetic status is not going to lower their risk. There are other things, brain health habits, that are really important, that patients should double down on: avoiding vascular disease, avoiding traumatic brain injury, excessive alcohol use, etcetera. It's a discussion that really tries to understand the motivations behind the testing. But some patients are very frank and they want to have it. They may want to contribute to the research community, and so in those instances we may offer it, but I also really want to make them understand that knowing a genetic diagnosis may be acceptable to them, but family members who are related to them may not wish to know. And they can really cause a lot of psychological stress that extends beyond the individual. And then that's something to really consider before actually pursuing testing. Dr Grouse: I think that's a really good reminder, especially about how this can even affect people outside of the patient themselves. I think a lot of us don't even think about that. And certainly, our patients may not either. Taking it a step further, thinking about newly available biomarkers, imaging modalities, how should we incorporate the use of these for our patients when we're suspicious of things like Alzheimer's disease or dementia with the Lewy bodies? Dr Scholz: So by and large these biomarkers are used in in the research area, but we can, in a given patient where maybe the clinical presentation is somewhat atypical, we can use it to help with our diagnostic impression. It doesn't get rid of the clinical evaluation, but at least it gives us a little bit more certainty. Here are the you know, the molecular features, the abnormal amyloid tau deposits, for example, that we're there we're detecting supports diagnosis. May also sometimes help in patients where we suspect there could be even the co-pathology going on where we get a mixture of features, where we can counsel the patients and you know, detecting copathologies is something that is certainly challenging. We know that patients who have more pathologies on average are not doing as well as the ones who have relatively pure disease forms. But this is also an area of intense research and as long as it's used judiciously to help with the diagnostic compression, to reduce a diagnostic odyssey, I think there's a lot of potential there to improve the clinical evaluations nowadays. Dr Grouse: It is really exciting to see the options that are opening up as the years go by, which brings me to my next question. There is certainly, as we know, this new category of disease modifying therapies that are available in the form of the anti-amyloid immunotherapies. What else do you think's on the horizon for treatment and prevention, neurodegenerative dementias, going down the road five, ten, fifteen years down the line?  Dr Scholz: Yeah, I think we're entering the era of precision medicine already and we're, we're seeing it already with the anti-amyloid therapies. By and large, I think the standard of care is going to be a multidisciplinary individualized treatment plan that incorporates a more holistic view. It incorporates diet, lifestyle factors, symptomatic management, but also disease modification strategies and potentially even multitarget disease modifying strategies. I think there's a lot more work that we have to do, especially in in the non-Alzheimer's dementia field. But overall, we're becoming much better in refining our diagnostic impression and in treating some of the complications that arise in these very complex diseases.  Dr Grouse: I'm curious, with the future of dementia care and diagnosis being more of a precision medicine model, how do you think this will be possible in an aging population with already, I think, probably a limited access to neurologists even in current state? Dr Scholz: Yeah, this is- these are these are very challenging societal questions. Increasingly, you know, we can use modern technologies such as televisits for follow up, but also, you know, remote monitoring devices. We have to educate the next generation, we need more neurologists, we can't do it alone; but we also need to empower primary care doctors who are usually the first go-to person. And perhaps biomarker testing will become much more common even in the primary care setting. I think overall, you know, we can tackle it by educating the community, empowering participants in various clinical trials, and being flexible of embracing certain new technologies. Dr Grouse: Absolutely. I think that makes a lot of sense and hopefully this will be another call to arms to try to get the word out, get more access to neurology and more people interested and like you said, getting our other colleagues involved and being able to manage it as well.  Dr Scholz: Yeah.  Dr Grouse: I wanted to transition a little bit into learning more about you. How did you become interested in genetics of neurodegenerative dementias? Dr Scholz: Yeah, it's something, it's an interest that has grown gradually. I started out as a neuroscientist in in Austria, where I was fortunate to work with a group that was very strongly involved in Parkinson's disease care. And I was so thrilled to see patients, you know, treated with deep brain stimulation. But yet in the same clinic, I also saw the patients who were not eligible because they had atypical neurodegenerative diseases. And it's the realization that there is such a broad spectrum of diseases that we frankly don't understand very well, that we really need to work with, understand and hopefully develop the treatments with. That's really has resonated with me. And I've since then really built my entire career around it through different countries at the United Kingdom and the United States. And I'm very fortunate to work at the National Institutes of Health, where I can pursue a lot of these research passions and work with interesting patients and colleagues.  Dr Grouse: Well, I've learned a lot today, and I'm sure our listeners would agree. Thank you so much for joining us. It's really been a pleasure speaking with you.  Dr Scholz: Well, thank you so much for allowing me to contribute. And, you know, I hope the review article conveys a lot of the exciting developments in this really challenging field. But there's loads of hope that we will eventually get to the point to tackle these conditions.  Dr Grouse: I encourage all of our listeners to check out Dr Scholz 's article. It is a great overview of these conditions and the genetics and neuropathology underlining them. Again, thank you so much.  Dr Scholz: Thank you for having me. Dr Grouse: Again, today I've been interviewing Dr Sonia Scholz, whose article on genetics and neuropathology of neurodegenerative dementias appears in the most recent issue of Continuum on dementia. Be sure to check out Continuum audio episodes from this and other issues. And thank you to our listeners for joining today. Dr Monteith: This is Dr Teshamae Monteith, associate editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use this link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/AudioCME. Thank you for listening to Continuum Audio.

In this episode of Clinical Lab Chat, CLP's Director of Business Intelligence, Chris Wolski, discusses the how and why of making precise clinical diagnosis of neurodegenerative diseases with Russ Lebovitz, MD, PhD, co-founder and CEO of Amprion. Among the topics they discuss:The critical importance of making accurate diagnoses of neurodegenerative diseasesWhy alpha-synuclein is an accurate biomarker for a number of degenerative diseases, including Alzheimer'sHow adding neurodegenerative testing to the routine diagnostic menu would benefit patients and their caregiversWhy we're entering a neurological healthcare “golden age”

Alterity Therapeutics (ASX:ATH) CEO Dr. David Stamler talked with Proactive's Tylah Tully about the company's advancements in therapies for neurodegenerative diseases, with a focus on multiple system atrophy (MSA). Dr. Stamler outlined the unique mechanism of action of their lead drug, which targets excess iron in the brain to address neurodegeneration. He emphasised the importance of early intervention, highlighting results from the company's open-label study, where 30% of late-stage MSA patients showed neurological improvement. “What we showed is that in those patients that responded, they actually had stabilisation of biomarkers,” said Dr. Stamler. Alterity anticipates data from its pivotal Phase 2 trial early next year, with plans to explore accelerated approval pathways or move into Phase 3 trials. The potential market for the drug is significant, with over 15,000 MSA patients in the US alone, and projected peak sales exceeding $1 billion USD. Dr. Stamler also shared insights into expanding the drug's application to other conditions, including Parkinson's disease and Friedrich's ataxia. #ProactiveInvestors #AlterityTherapeutics #ASX #MSATreatment #NeurodegenerativeDiseases #BiotechInnovation #HealthcareResearch #RareDiseases #ParkinsonianDisorders #FriedrichsAtaxia #ClinicalTrials

David Perlmutter, MD, FACN, ABIHM, joins Integrative Practitioner Content Specialist Avery St. Onge to discuss new research on the fundamental role of brain microglial cells in the development of neurodegenerative disorders and how they could be targeted for new treatments. This episode is brought to you by the Integrative Healthcare Symposium. Register for the Symposium and receive 15% off with promo code IP2025PODCAST: https://xpressreg.net/register/ihsy0225/landing.php?sc=IP2025PODCAST Learn more about the event by visiting the Symposium website: www.ihsymposium.com Contact the Integrative Healthcare Symposium team: info@ihsymposium.com Find us at integrativepractitioner.com or e-mail us at IPEditor@divcom.com. Theme music: "Upbeat Party" by Scott Holmes via freemusicarchive.org, "Carefree" by Kevin Mcleod via incompetech.com, and “Relaxing Light Background” by AudioCoffee.

In today's episode, we dive into the critical role of phospholipids in maintaining brain health, examining how these molecules contribute to neuronal communication, synaptic plasticity, and cognitive resilience. We'll explore the biochemical structure and function of key phospholipids like phosphatidylserine and phosphatidylcholine within neuronal membranes, where they play indispensable roles. We discuss associations and impacts of environmental toxins, aging, and neurodegenerative conditions. Finally, we discuss dietary tools to support phospholipid levels and promote cognitive health. Topics: 1. Introduction to Phospholipids and Cognitive Health 2. Brain Cell Structure and Composition - Neurons, glial cells. 3. Detailed Anatomy of Neurons - Soma contains organelles, dendrites receive signals, axon sends impulses. - Myelin sheath insulates axon, speeding signal transmission. - Myelin is rich in phospholipids. 4. Roles of Glial Cells in Brain Health - Astrocytes, oligodendrocytes, and microglia support neurons. - Glial cells regulate the brain's environment, form myelin, and provide immune defense. - Phospholipid-rich membranes are essential for glial function. 5. Biochemistry: Phospholipids - Phospholipids have a glycerol backbone, fatty acid tails, and a phosphate group. - Hydrophilic and hydrophobic parts form bilayers. - Key phospholipids: PC, PE, PS, PI 6. Phospholipid Bilayer's Role in Neuronal Communication - Ion channels, receptors, and transporters in the bilayer enable cell functions. - Ion channels allow ions to flow, creating signals for neuron communication. - Receptors detect neurotransmitters, initiating responses. 7. Neuronal Activation and Electrochemical Gradients - Resting neurons have ion concentration differences inside and outside the cell. - Ion channel activity during activation creates an action potential. - The phospholipid membrane enables controlled ion flow for signal transmission. 8. Neurotransmitter Release - Action potential at axon terminal triggers calcium entry. - Calcium causes vesicles to release neurotransmitters. - Released neurotransmitters bind to receptors, continuing the signal. 9. Diversity of Phospholipids in Neuronal Membranes - Different phospholipids (PC, PE, PS, PI) are essential for membrane integrity. 10. Summary: Phospholipids in Brain Function and Cognitive Health - Phospholipids support neuronal communication, synaptic plasticity, and cognitive resilience. - Synaptic plasticity - essential for learning and memory. 11. Phospholipid Disruption and Cognitive Decline - Oxidative stress, aging, and inflammation disrupt phospholipid composition. - Lipid peroxidation damages membranes, affecting neuron signaling. - Phospholipid damage contributes to cognitive decline. 12. Importance of Phospholipids in Aging and Brain Health - Lipid levels decrease with age, impacting brain function. 13. Environmental Toxins and the Brain - Heavy metals like mercury cause oxidative damage to phospholipids. - Damaged phospholipids and impaired neuron function. 14. Consequences of Suboptimal Phospholipids - Cognitive symptoms. - Low levels seen in neurodegenerative conditions. 15. Tools for Supporting Phospholipid Levels - Foods with PS and PC, such as fatty fish and eggs. - Phospholipid supplements. Thanks for tuning in! "⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠75 Gut-Healing Strategies & Biohacks⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠" Follow Chloe on Instagram ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@synthesisofwellness⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Follow Chloe on TikTok @chloe_c_porter Visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠synthesisofwellness.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ --- Support this podcast: https://podcasters.spotify.com/pod/show/chloe-porter6/support

Proteins are large biomolecules that play critical roles in a host of cellular processes, from cell signaling to regulating the immune system. However, these life-giving proteins can form toxic aggregate species that have been linked to several neurodegenerative diseases, including Alzheimer's Disease and Parkinson's Disease. In this program, UC Santa Barbara professor Joan-Emma Shea discusses the tau protein as a model system to study neurodegeneration. Shea says this protein plays a functional role in stabilizing microtubules in brain cells, but it can also self-assemble to form amyloid fibrils (large “clumps” of Tau proteins). There are several neurodegenerative diseases linked to tau assembly, including Alzheimer's Disease, Pick's Disease, and chronic traumatic encephalopathy, and they are collectively known as tauopathies. Shea discusses new insights into tauopathies and targets for therapeutics. Series: "GRIT Talks" [Science] [Show ID: 40083]

Proteins are large biomolecules that play critical roles in a host of cellular processes, from cell signaling to regulating the immune system. However, these life-giving proteins can form toxic aggregate species that have been linked to several neurodegenerative diseases, including Alzheimer's Disease and Parkinson's Disease. In this program, UC Santa Barbara professor Joan-Emma Shea discusses the tau protein as a model system to study neurodegeneration. Shea says this protein plays a functional role in stabilizing microtubules in brain cells, but it can also self-assemble to form amyloid fibrils (large “clumps” of Tau proteins). There are several neurodegenerative diseases linked to tau assembly, including Alzheimer's Disease, Pick's Disease, and chronic traumatic encephalopathy, and they are collectively known as tauopathies. Shea discusses new insights into tauopathies and targets for therapeutics. Series: "GRIT Talks" [Science] [Show ID: 40083]

Proteins are large biomolecules that play critical roles in a host of cellular processes, from cell signaling to regulating the immune system. However, these life-giving proteins can form toxic aggregate species that have been linked to several neurodegenerative diseases, including Alzheimer's Disease and Parkinson's Disease. In this program, UC Santa Barbara professor Joan-Emma Shea discusses the tau protein as a model system to study neurodegeneration. Shea says this protein plays a functional role in stabilizing microtubules in brain cells, but it can also self-assemble to form amyloid fibrils (large “clumps” of Tau proteins). There are several neurodegenerative diseases linked to tau assembly, including Alzheimer's Disease, Pick's Disease, and chronic traumatic encephalopathy, and they are collectively known as tauopathies. Shea discusses new insights into tauopathies and targets for therapeutics. Series: "GRIT Talks" [Science] [Show ID: 40083]

Proteins are large biomolecules that play critical roles in a host of cellular processes, from cell signaling to regulating the immune system. However, these life-giving proteins can form toxic aggregate species that have been linked to several neurodegenerative diseases, including Alzheimer's Disease and Parkinson's Disease. In this program, UC Santa Barbara professor Joan-Emma Shea discusses the tau protein as a model system to study neurodegeneration. Shea says this protein plays a functional role in stabilizing microtubules in brain cells, but it can also self-assemble to form amyloid fibrils (large “clumps” of Tau proteins). There are several neurodegenerative diseases linked to tau assembly, including Alzheimer's Disease, Pick's Disease, and chronic traumatic encephalopathy, and they are collectively known as tauopathies. Shea discusses new insights into tauopathies and targets for therapeutics. Series: "GRIT Talks" [Science] [Show ID: 40083]

Neurodegenerative diseases such as Parkinson's, Alzheimer's, Multiple Sclerosis, ALS, are “chronic conditions that damage and destroy parts of your nervous system over time, especially your brain.” According to mainstream medicine, “these conditions are permanent and incurable, but many are now treatable thanks to medical advances. Currently, the main goal is to treat the symptoms and slow the progress of these conditions when possible”.  We also know that neurodegenerative disorders are the leading cause of physical and cognitive disability around the globe, affecting 15% of the world population, and are expected to double over the next two decades. Given that neurological disorders are so prevalent and on the rise, and given that mainstream medicine has few options other than symptom management, it is vital for the prevention and reversal of neurodegenerative disease to look elsewhere. Integrative and Functional Medicine has a lot more answers to neurodegeneration than mainstream medicine, and Dr. Ken Sharlin is a neurologist who has transformed his conventional neurology practice to incorporate more integrative and functional medicine approaches into his practice for better patient outcomes.  In this episode of the MindHealth360 Show, we are joined by Dr. Ken Sharlin, author of *The Healthy Brain Toolbox*, who shares his journey from conventional neurology to a more holistic practice, emphasising the importance of addressing lifestyle, environmental factors, and personalised medicine in treating conditions like Parkinson's, Alzheimer's and MS. Dr. Sharlin discusses how modern neurology has traditionally focused on diagnosis and limited treatment options, often missing the opportunity to explore and address the root causes of neurological diseases. He explains that while medications and surgeries are valuable, they represent only a portion of the available tools. By incorporating functional medicine principles, including therapeutic lifestyle changes, environmental toxin mitigation, and addressing metabolic syndromes like "diabesity," Dr. Sharlin has expanded his toolbox to offer more comprehensive and effective care.  One of the critical insights from Dr. Sharlin is the role of the gut-brain connection and how gut health can significantly influence brain health, particularly in neurodegenerative diseases. He also delves into the emerging role of mitochondrial dysfunction and oxidative stress as primary drivers of diseases like Parkinson's. Dr. Sharlin emphasises the importance of early intervention and personalised care, recognising that no two patients are the same, even when they have identical diagnoses.

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter In this special episode, Peter provides a comprehensive introduction to longevity, perfect for newcomers or those looking to refresh their knowledge. He lays out the foundational concepts of lifespan, healthspan, and the marginal decade. Additionally, Peter discusses the four main causes of death and their prevention, as well as detailing the five key strategies in his longevity toolkit to improve lifespan and healthspan. Detailed show notes provide links for deeper exploration of these topics, making it an ideal starting point for anyone interested in understanding and improving their longevity. We discuss: Key points about starting exercise as an older adult [2:45]; Overview of episode topics and structure [1:45]; How Peter defines longevity [3:45]; Why healthspan is a crucial component of longevity [11:15]; The evolution of medicine from medicine 1.0 to 2.0, and the emergence of medicine 3.0 [15:30]; Overview of atherosclerotic diseases: the 3 pathways of ASCVD, preventative measures, and the impact of metabolic health [26:00]; Cancer: genetic and environmental factors, treatment options, and the importance of early and aggressive screening [33:15]; Neurodegenerative diseases: causes, prevention, and the role of genetics and metabolic health [39:30]; The spectrum of metabolic diseases [43:15]; Why it's never too late to start thinking about longevity [44:15]; The 5 components of the longevity toolkit [46:30]; Peter's framework for exercise—The Centenarian Decathlon [47:45]; Peter's nutritional framework: energy balance, protein intake, and more [58:45]; Sleep: the vital role of sleep in longevity, and how to improve sleep habits [1:08:30]; Drugs and supplements: Peter's framework for thinking about drugs and supplements as tools for enhancing longevity [1:13:30]; Why emotional health is a key component of longevity [1:17:00]; Advice for newcomers on where to start on their longevity journey [1:19:30]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube

Neurodegenerative disease is the subject of this month's Editors' Choice podcast, with Dr. Patrick Cullinane¹ and Dr. Zane Jaunmuktane.¹ They join the podcast for an overview of brain examination, explaining the process of protein misfolding, the spread of pathology through the brain, and what new discoveries can tell us about old diseases. Read the paper: Pathology of neurodegenerative disease for the general neurologist 1. Queen Square Brain Bank for Neurological Disorders, UCL Queen Square Institute of Neurology, London, UK Please subscribe to the Practical Neurology podcast on your favourite platform to get the latest episodes. If you enjoy our podcast, you can leave us a review or a comment on Apple Podcasts (https://apple.co/3vVPClm) or Spotify (https://spoti.fi/4baxjsQ). We'd love to hear your feedback on social media - @PracticalNeurol. This episode was hosted by PN's podcast editor Dr. Amy Ross Russell. Production by Letícia Amorim, Brian O'Toole, and Amy Ross Russell. Editing by Brian O'Toole. Special thanks to The Podcast Studios Dublin for their assistance with the recording of this episode, and thank you for listening.

About the Guest(s): Dr. Kristin Hieshetter is a highly respected figure in the realm of functional health, demonstrated extensively through her dedication to educating others about the significance of comprehensive healthcare. Although her full professional history is not discussed, it is clear from the transcript that she is passionate about helping people understand their health better. Dr. Hieshetter appears to be knowledgeable about topics like excitotoxins and their impact on the human body, advocating for natural and preventative approaches to health. Episode Summary: In the latest enlightening episode of Functional Health Radio, Dr. Kristin Hieshetter dives deep into the startling downward trend of life expectancy in the United States and the rising chronic diseases among children. Initiating the conversation with disturbing healthcare statistics, she pivots to discuss the overlooked dangers of excitotoxins in our diet, linking them to neurodegenerative diseases. The episode is rich with alarming yet vital information, balancing medical insights with actionable health tips. Dr. Hieshetter references the worrying trend of decreasing life expectancy in the U.S. and contrasts it with the exorbitant healthcare spending, posing the question of what can be done differently. She introduces Dr. Russell Blaylock's research on excitotoxins, pulling lessons from historical examples such as the Chamorro Indians of Guam to underscore the dangers of dietary neurotoxins like glutamate and aspartate. The episode artfully blends anecdotes with science to underline the proposition that current dietary habits could pose a risk to neurological health, emphasizing the importance of magnesium and antioxidants for brain protection. Key Takeaways: U.S. life expectancy has fallen, and chronic diseases in children are at unprecedented rates, suggesting an urgent need for a healthcare paradigm shift. Excitotoxins like glutamate can build up to toxic levels in the brain, with prolonged exposure leading to devastating neurological diseases. Early exposure to excitotoxins has been linked to neurodegeneration, even decades later, elevating the importance of cutting these toxins from our diets. Dietary antioxidants and nutrients such as vitamin C, E, glutathione, magnesium, and omega-3 fatty acids are emphasized as crucial for brain health and protection. The role of excitotoxins in neurodegenerative conditions and the pivotal importance of dietary changes for prevention and recovery are central themes. Notable Quotes: "We are walking around in the most amazing, intelligent, responsive, adapting, and aware system in the world, the human body." "Excitotoxins can sometimes be linked to those disease processes in the body." "The clinical symptoms of most neurodegenerative diseases don't show up until 80% to 90% of specific cells in the spinal cord or specific regions of the brain are dead or damaged." "Magnesium is your brain's most powerful protector." "Eat your fresh fruits and vegetables, they're critical for your survival." Resources: The resources mentioned include: Dr. Russell Blaylock's book "Excitotoxins: The Taste That Kills" Studies cited by Dr. Kristin Hieshetter: The works of scientists George Spencer, Leonard Kerland, and more from the 1950s to 1980s on the Chamorro Indians and excitotoxins. Functional Health Mastery For a comprehensive understanding of the ways to protect your brain from excitotoxins and the power of a natural diet, listen to the full episode. Don't forget to tune in to Functional Health Radio for more discussions that can revolutionize your approach to health and well-being.

Looking 4 Healing Radio with Dr. Bryan Ardis – Some of the benefits you are going to learn about have proven to help prevent reverse Neurodegenerative diseases like Parkinson's and Alzheimer's. To improve cardiovascular disease, reversing a weak heart's ability to pump blood even enhanced. Something called the ejection fraction, which is how much blood is pumped by the heart to the rest of the body, just supplementing taurine for a few months...

Looking 4 Healing Radio with Dr. Bryan Ardis – Some of the benefits you are going to learn about have proven to help prevent reverse Neurodegenerative diseases like Parkinson's and Alzheimer's. To improve cardiovascular disease, reversing a weak heart's ability to pump blood even enhanced. Something called the ejection fraction, which is how much blood is pumped by the heart to the rest of the body, just supplementing taurine for a few months...

Naila brings you 21 articles from January 2024, on non-pharmacological approaches to the prevention and intervention of Alzheimer's disease. You'll be treated to research from computational modeling, to rodent models, to clinical trials, with a particular focus on optimizing and personalizing intervention strategies. This episode also covers some research on the role of caregivers, and several papers consider the socioeconomic and ethnographic context in which these studies take place. Let's get to it! Stimulation Techniques (7)Exercise (3)Cognitive Training (2)  Art Therapy and Dyad Interventions (4)Lifestyle Interventions and Prevention (5)-------------------------------------------------------------- You can find the bibliography for this episode here, or by clicking the link below:https://drive.google.com/file/d/1-NvZsr9qousOnp51vDbtMxX4RQe7Elrd/view?usp=drive_linkTo access the folder with ALL our bibliographies, follow this link (it will be updated as we publish episodes and process bibliographies), or use the link below:https://drive.google.com/drive/folders/1bzSzkY9ZHzzY8Xhzt0HZfZhRG1Gq_Si-?usp=sharingYou can also find all of our bibliographies on our website: amindr.com. -------------------------------------------------------------- Follow-up on social media for more updates!Twitter: @AMiNDR_podcastInstagram: @AMiNDR.podcastFacebook:  AMiNDR  Youtube: AMiNDR PodcastLinkedIn: AMiNDR PodcastEmail: amindrpodcast@gmail.com  -------------------------------------------------------------- Please help us spread the word about AMiNDR to your friends, colleagues, and networks! And if you could leave us a rating and/or review on your streaming app of choice (Apple Podcasts, Spotify, or wherever you listen to the podcast), that would be greatly appreciated! It helps us a lot and we thank you in advance for leaving a review! Don't forget to subscribe to hear about new episodes as they come out too. Thank you to our sponsor, the Canadian Consortium of Neurodegeneration in Aging, or CCNA, for their financial support of this podcast. This helps us to stay on the air and bring you high quality episodes. You can find out more about the CCNA on their website: https://ccna-ccnv.ca/. Our team of volunteers works tirelessly each month to bring you every episode of AMiNDR. This episode was scripted and hosted by Naila Kuhlmann, edited by Isabelle Vaux, and reviewed by Anusha Kamesh. The bibliography and wordcloud were created by Salodin Al-Achkar (www.wordart.com). Big thanks to the sorting team for taking on the enormous task of sorting all of the Alzheimer's Disease papers into episodes each month. For January 2024, the sorters were Elyn Rowe, Christy Yu, Salodin Al-Achkar, Naila Kuhlmann, Yonjoon Shin, Ali Mithani, and Ben Cornish. Also, props to our management team, which includes Sarah Louadi, Ellen Koch, Naila Kuhlmann, Elyn Rowe, Anusha Kamesh, Lara Onbasi, Joseph Liang, Judy Cheng, and Christy Yu, for keeping everything running smoothly. AMiNDR was founded in 2020 by Sarah Louadi, Ellen Koch, Elyn Rowe, and Naila Kuhlmann. Our music is from "Journey of a Neurotransmitter" by musician and fellow neuroscientist Anusha Kamesh; you can find the original piece and her other music on soundcloud under Anusha Kamesh or on her YouTube channel, AKMusic.   https://www.youtube.com/channel/UCMH7chrAdtCUZuGia16FR4w   -------------------------------------------------------------- If you are interested in joining the team, send us your CV by email. We are specifically looking for help with sorting abstracts by topic, abstract summaries and hosting, audio editing, creating bibliographies, and outreach/marketing. However, if you are interested in helping in other ways, don't hesitate to apply anyways.  --------------------------------------------------------------*About AMiNDR: *  Learn more about this project and the team behind it by listening to our first episode: "Welcome to AMiNDR!"

Join Christy for 12 papers from January 2024 on structural neuroimaging in the diagnosis of Alzheimer's disease. This episode is a bit different from past ones because it's all about the use of machine learning and deep learning. Whether you're an AI researcher or simply curious about the topic, you won't want to miss this episode. Detecting AD (3:42)  Predictions, associations or comparisons (16:48)-------------------------------------------------------------- You can find the bibliography for this episode here, or by clicking the link below:https://drive.google.com/file/d/1A4HZVCtgh5AwZkd5V2ATZSFAxGJt48q3/view?usp=drive_linkTo access the folder with ALL our bibliographies, follow this link (it will be updated as we publish episodes and process bibliographies), or use the link below:https://drive.google.com/drive/folders/1bzSzkY9ZHzzY8Xhzt0HZfZhRG1Gq_Si-?usp=sharingYou can also find all of our bibliographies on our website: amindr.com. -------------------------------------------------------------- Follow-up on social media for more updates!Twitter: @AMiNDR_podcastInstagram: @AMiNDR.podcastFacebook:  AMiNDR  Youtube: AMiNDR PodcastLinkedIn: AMiNDR PodcastEmail: amindrpodcast@gmail.com  -------------------------------------------------------------- Please help us spread the word about AMiNDR to your friends, colleagues, and networks! And if you could leave us a rating and/or review on your streaming app of choice (Apple Podcasts, Spotify, or wherever you listen to the podcast), that would be greatly appreciated! It helps us a lot and we thank you in advance for leaving a review! Don't forget to subscribe to hear about new episodes as they come out too. Thank you to our sponsor, the Canadian Consortium of Neurodegeneration in Aging, or CCNA, for their financial support of this podcast. This helps us to stay on the air and bring you high quality episodes. You can find out more about the CCNA on their website: https://ccna-ccnv.ca/. Our team of volunteers works tirelessly each month to bring you every episode of AMiNDR. This episode was scripted and hosted by Christy Yu, edited by Michelle Grover, and reviewed by Anusha Kamesh. The bibliography and wordcloud were created by Salodin Al-Achkar (www.wordart.com). Big thanks to the sorting team for taking on the enormous task of sorting all of the Alzheimer's Disease papers into episodes each month. For January 2024, the sorters were Elyn Rowe, Christy Yu, Salodin Al-Achkar, Naila Kuhlmann, Yonjoon Shin, Ali Mithani, and Ben Cornish. Also, props to our management team, which includes Sarah Louadi, Ellen Koch, Naila Kuhlmann, Elyn Rowe, Anusha Kamesh, Lara Onbasi, Joseph Liang, Judy Cheng, and Christy Yu, for keeping everything running smoothly. AMiNDR was founded in 2020 by Sarah Louadi, Ellen Koch, Elyn Rowe, and Naila Kuhlmann. Our music is from "Journey of a Neurotransmitter" by musician and fellow neuroscientist Anusha Kamesh; you can find the original piece and her other music on soundcloud under Anusha Kamesh or on her YouTube channel, AKMusic.   https://www.youtube.com/channel/UCMH7chrAdtCUZuGia16FR4w   -------------------------------------------------------------- If you are interested in joining the team, send us your CV by email. We are specifically looking for help with sorting abstracts by topic, abstract summaries and hosting, audio editing, creating bibliographies, and outreach/marketing. However, if you are interested in helping in other ways, don't hesitate to apply anyways.  --------------------------------------------------------------*About AMiNDR: *  Learn more about this project and the team behind it by listening to our first episode: "Welcome to AMiNDR!" 

Another series of AMiNDR kicks off with this episode. Anusha takes you through 7 papers published in January 2024 targeting neuroprotection in AD. If you'd like to hear about potential compounds that could reduce neurodegeneration in Alzheimer's disease, this is the episode for you.Testing for neuroprotection in cell lines (2:57)Testing for neuroprotection using in vivo AD models (11:47)-------------------------------------------------------------- You can find the bibliography for this episode here, or by clicking the link below:https://drive.google.com/file/d/1A4HZVCtgh5AwZkd5V2ATZSFAxGJt48q3/view?usp=drive_linkTo access the folder with ALL our bibliographies, follow this link (it will be updated as we publish episodes and process bibliographies), or use the link below:https://drive.google.com/drive/folders/1bzSzkY9ZHzzY8Xhzt0HZfZhRG1Gq_Si-?usp=sharingYou can also find all of our bibliographies on our website: amindr.com. -------------------------------------------------------------- Follow-up on social media for more updates!Twitter: @AMiNDR_podcastInstagram: @AMiNDR.podcastFacebook:  AMiNDR  Youtube: AMiNDR PodcastLinkedIn: AMiNDR PodcastEmail: amindrpodcast@gmail.com  -------------------------------------------------------------- Please help us spread the word about AMiNDR to your friends, colleagues, and networks! And if you could leave us a rating and/or review on your streaming app of choice (Apple Podcasts, Spotify, or wherever you listen to the podcast), that would be greatly appreciated! It helps us a lot and we thank you in advance for leaving a review! Don't forget to subscribe to hear about new episodes as they come out too. Thank you to our sponsor, the Canadian Consortium of Neurodegeneration in Aging, or CCNA, for their financial support of this podcast. This helps us to stay on the air and bring you high quality episodes. You can find out more about the CCNA on their website: https://ccna-ccnv.ca/. Our team of volunteers works tirelessly each month to bring you every episode of AMiNDR. This episode was scripted and hosted by Anusha Kamesh, edited by Scott Prins, and reviewed by Naila Kuhlmann. The bibliography and wordcloud were created by Salodin Al-Achkar (www.wordart.com). Big thanks to the sorting team for taking on the enormous task of sorting all of the Alzheimer's Disease papers into episodes each month. For January 2024, the sorters were Elyn Rowe, Christy Yu, Salodin Al-Achkar, Naila Kuhlmann, Yonjoon Shin, Ali Mithani, and Ben Cornish. Also, props to our management team, which includes Sarah Louadi, Ellen Koch, Naila Kuhlmann, Elyn Rowe, Anusha Kamesh, Lara Onbasi, Joseph Liang, Judy Cheng, and Christy Yu, for keeping everything running smoothly. AMiNDR was founded in 2020 by Sarah Louadi, Ellen Koch, Elyn Rowe, and Naila Kuhlmann. Our music is from "Journey of a Neurotransmitter" by musician and fellow neuroscientist Anusha Kamesh; you can find the original piece and her other music on soundcloud under Anusha Kamesh or on her YouTube channel, AKMusic.   https://www.youtube.com/channel/UCMH7chrAdtCUZuGia16FR4w   -------------------------------------------------------------- If you are interested in joining the team, send us your CV by email. We are specifically looking for help with sorting abstracts by topic, abstract summaries and hosting, audio editing, creating bibliographies, and outreach/marketing. However, if you are interested in helping in other ways, don't hesitate to apply anyways.  --------------------------------------------------------------*About AMiNDR: *  Learn more about this project and the team behind it by listening to our first episode: "Welcome to AMiNDR!" 

Another special episode to help kick off our return! In what we hope to be a recurring special series, an interview with members in our scholarly community on navigating the multiple facets of life as a scientist. In the first episode, host Kevin Nishimura interviews one of our own Joseph Liang on his personal journey to and through graduate school. Tune in to learn what he has to say about getting into graduate school, and how his perspective on the journey has changed since he's started! We hope you enjoy, and please let us know if you want to hear more episodes like this! To access the folder with ALL our bibliographies from past episodes, follow this link (it will be updated as we publish episodes and process bibliographies), or use the link below:https://drive.google.com/drive/folders/1bzSzkY9ZHzzY8Xhzt0HZfZhRG1Gq_Si-?usp=sharingYou can also find all of our bibliographies on our website: amindr.com. -------------------------------------------------------------- Follow-up on social media for more updates!Twitter: @AMiNDR_podcastInstagram: @AMiNDR.podcastFacebook:  AMiNDR  Youtube: AMiNDR PodcastLinkedIn: AMiNDR PodcastEmail: amindrpodcast@gmail.com  -------------------------------------------------------------- Please help us spread the word about AMiNDR to your friends, colleagues, and networks! And if you could leave us a rating and/or review on your streaming app of choice (Apple Podcasts, Spotify, or wherever you listen to the podcast), that would be greatly appreciated! It helps us a lot and we thank you in advance for leaving a review! Don't forget to subscribe to hear about new episodes as they come out too. Our team of volunteers works tirelessly each month to bring you every episode of AMiNDR. This episode was hosted by Kevin Nishimura, edited by Joseph Liang, and reviewed by Anusha Kamesh. The episode art was created by Salodin Al-Achkar.Big thanks to the sorting team for taking on the enormous task of sorting all of the Alzheimer's Disease papers into episodes each month. For November 2023, the sorters were Elyn Rowe, Christy Yu, Salodin Al-Achkar, Naila Kuhlmann and Anusha Kamesh. Also, props to our management team, which includes Sarah Louadi, Ellen Koch, Naila Kuhlmann, Elyn Rowe, Anusha Kamesh, Lara Onbasi, Joseph Liang, Judy Cheng, and Christy Yu, for keeping everything running smoothly. AMiNDR was founded in 2020 by Sarah Louadi, Ellen Koch, Elyn Rowe, and Naila Kuhlmann. Our music is from "Journey of a Neurotransmitter" by musician and fellow neuroscientist Anusha Kamesh; you can find the original piece and her other music on soundcloud under Anusha Kamesh or on her YouTube channel, AKMusic.   https://www.youtube.com/channel/UCMH7chrAdtCUZuGia16FR4w   -------------------------------------------------------------- If you are interested in joining the team, send us your CV by email. We are specifically looking for help with sorting abstracts by topic, abstract summaries and hosting, audio editing, creating bibliographies, and outreach/marketing. However, if you are interested in helping in other ways, don't hesitate to apply anyways.  --------------------------------------------------------------*About AMiNDR: *  Learn more about this project and the team behind it by listening to our first episode: "Welcome to AMiNDR!" 

Join us as we cover a set of papers published in November 2023 on treatments targeting cholinergic transmission in Alzheimer's disease. In this episode hosted by Christy, we will go over various topics, from drug discovery using synthesized compounds to drug testing of plant extracts, as well as improving drug delivery through the blood-brain barrier. Enjoy! Papers evaluating synthesized compounds (2:00)  Papers targeting AchE (10:45)-------------------------------------------------------------- You can find the bibliography for this episode here, or by clicking the link below:https://drive.google.com/file/d/1wh1EFtB3KrW0J6CHd_i-NxOaSZxZdXyT/view?usp=drive_linkTo access the folder with ALL our bibliographies, follow this link (it will be updated as we publish episodes and process bibliographies), or use the link below:https://drive.google.com/drive/folders/1bzSzkY9ZHzzY8Xhzt0HZfZhRG1Gq_Si-?usp=sharingYou can also find all of our bibliographies on our website: amindr.com. -------------------------------------------------------------- Follow-up on social media for more updates!Twitter: @AMiNDR_podcastInstagram: @AMiNDR.podcastFacebook:  AMiNDR  Youtube: AMiNDR PodcastLinkedIn: AMiNDR PodcastEmail: amindrpodcast@gmail.com  -------------------------------------------------------------- Please help us spread the word about AMiNDR to your friends, colleagues, and networks! And if you could leave us a rating and/or review on your streaming app of choice (Apple Podcasts, Spotify, or wherever you listen to the podcast), that would be greatly appreciated! It helps us a lot and we thank you in advance for leaving a review! Don't forget to subscribe to hear about new episodes as they come out too. Thank you to our sponsor, the Canadian Consortium of Neurodegeneration in Aging, or CCNA, for their financial support of this podcast. This helps us to stay on the air and bring you high quality episodes. You can find out more about the CCNA on their website: https://ccna-ccnv.ca/. Our team of volunteers works tirelessly each month to bring you every episode of AMiNDR. This episode was scripted and hosted by Christy Yu, edited by Isabelle Vaux, and reviewed by Anusha Kamesh. The bibliography was made by Rob Cloke and wordcloud was created by Salodin Al-Achkar (www.wordart.com). Big thanks to the sorting team for taking on the enormous task of sorting all of the Alzheimer's Disease papers into episodes each month. For November 2023, the sorters were Elyn Rowe, Christy Yu, Salodin Al-Achkar, Naila Kuhlmann and Anusha Kamesh. Also, props to our management team, which includes Sarah Louadi, Ellen Koch, Naila Kuhlmann, Elyn Rowe, Anusha Kamesh, Lara Onbasi, Joseph Liang, Judy Cheng, and Christy Yu, for keeping everything running smoothly. AMiNDR was founded in 2020 by Sarah Louadi, Ellen Koch, Elyn Rowe, and Naila Kuhlmann. Our music is from "Journey of a Neurotransmitter" by musician and fellow neuroscientist Anusha Kamesh; you can find the original piece and her other music on soundcloud under Anusha Kamesh or on her YouTube channel, AKMusic.   https://www.youtube.com/channel/UCMH7chrAdtCUZuGia16FR4w   -------------------------------------------------------------- If you are interested in joining the team, send us your CV by email. We are specifically looking for help with sorting abstracts by topic, abstract summaries and hosting, audio editing, creating bibliographies, and outreach/marketing. However, if you are interested in helping in other ways, don't hesitate to apply anyways.  --------------------------------------------------------------*About AMiNDR: *  Learn more about this project and the team behind it by listening to our first episode: "Welcome to AMiNDR!" 

As we get back up to speed on our regular episodes, we thought we'd treat you (and ourselves) to something out of the ordinary: a conversation on how visual storytelling can shape how we think - and feel - about Alzheimer's disease. Host Naila Kuhlmann had the pleasure of interviewing Gina Martin, who founded the Bob and Diane Fund to support and promote visual storytelling about Alzheimer's and dementia. Tune in to get the backstory on the fund, an auditory glimpse at the work of this year's winner, a discussion on the social narrative of Alzheimer's disease, and reflections on the role of the arts in shaping it. We hope you enjoy, and welcome your feedback and thoughts!Links:Bob and Diane Fund WebsiteBob and Diane Fund 2023 WinnerPiece of Mind: Virtual Performance on Dementia To access the folder with ALL our bibliographies from past episodes, follow this link (it will be updated as we publish episodes and process bibliographies), or use the link below:https://drive.google.com/drive/folders/1bzSzkY9ZHzzY8Xhzt0HZfZhRG1Gq_Si-?usp=sharingYou can also find all of our bibliographies on our website: amindr.com. -------------------------------------------------------------- Follow-up on social media for more updates!Twitter: @AMiNDR_podcastInstagram: @AMiNDR.podcastFacebook:  AMiNDR  Youtube: AMiNDR PodcastLinkedIn: AMiNDR PodcastEmail: amindrpodcast@gmail.com  -------------------------------------------------------------- Please help us spread the word about AMiNDR to your friends, colleagues, and networks! And if you could leave us a rating and/or review on your streaming app of choice (Apple Podcasts, Spotify, or wherever you listen to the podcast), that would be greatly appreciated! It helps us a lot and we thank you in advance for leaving a review! Don't forget to subscribe to hear about new episodes as they come out too. Our team of volunteers works tirelessly each month to bring you every episode of AMiNDR. This episode was hosted by Naila Kuhlmann, edited by Michelle Grover, and reviewed by Naila Kuhlmann. The episode art was created by Salodin Al-Achkar (www.wordart.com). Big thanks to the sorting team for taking on the enormous task of sorting all of the Alzheimer's Disease papers into episodes each month. For November 2023, the sorters were Elyn Rowe, Christy Yu, Salodin Al-Achkar, Naila Kuhlmann and Anusha Kamesh. Also, props to our management team, which includes Sarah Louadi, Ellen Koch, Naila Kuhlmann, Elyn Rowe, Anusha Kamesh, Lara Onbasi, Joseph Liang, Judy Cheng, and Christy Yu, for keeping everything running smoothly. AMiNDR was founded in 2020 by Sarah Louadi, Ellen Koch, Elyn Rowe, and Naila Kuhlmann. Our music is from "Journey of a Neurotransmitter" by musician and fellow neuroscientist Anusha Kamesh; you can find the original piece and her other music on soundcloud under Anusha Kamesh or on her YouTube channel, AKMusic.   https://www.youtube.com/channel/UCMH7chrAdtCUZuGia16FR4w   -------------------------------------------------------------- If you are interested in joining the team, send us your CV by email. We are specifically looking for help with sorting abstracts by topic, abstract summaries and hosting, audio editing, creating bibliographies, and outreach/marketing. However, if you are interested in helping in other ways, don't hesitate to apply anyways.  --------------------------------------------------------------*About AMiNDR: *  Learn more about this project and the team behind it by listening to our first episode: "Welcome to AMiNDR!" 

Hello listeners, it's been a while since we last released an episode but we are back with another series here at AMiNDR bringing you a synopsis of publications on Alzheimer's disease (AD) research on various topics that were released in November of 2023. In this episode, Anusha takes you through 11 papers testing potential neuroprotective agents for AD treatment. You'll hear about naturally and pharmaceutically-derived compounds as well as strategies that exploit cell-endogenous processes for neuroprotection in AD. Testing Naturally-Derived Compounds for Neuroprotective effects (3:53)Testing Cell-Endogenous Mechanisms for Neuroprotection (16:57)Testing Pharmaceutically-Derived Compounds for Neuroprotective effects (20:17)-------------------------------------------------------------- You can find the bibliography for this episode here, or by clicking the link below:https://drive.google.com/file/d/1cILUsT6aQY9go4n3e_veF4yawB-aTbwx/view?usp=drive_linkTo access the folder with ALL our bibliographies, follow this link (it will be updated as we publish episodes and process bibliographies), or use the link below:https://drive.google.com/drive/folders/1bzSzkY9ZHzzY8Xhzt0HZfZhRG1Gq_Si-?usp=sharingYou can also find all of our bibliographies on our website: amindr.com. -------------------------------------------------------------- Follow-up on social media for more updates!Twitter: @AMiNDR_podcastInstagram: @AMiNDR.podcastFacebook:  AMiNDR  Youtube: AMiNDR PodcastLinkedIn: AMiNDR PodcastEmail: amindrpodcast@gmail.com  -------------------------------------------------------------- Please help us spread the word about AMiNDR to your friends, colleagues, and networks! And if you could leave us a rating and/or review on your streaming app of choice (Apple Podcasts, Spotify, or wherever you listen to the podcast), that would be greatly appreciated! It helps us a lot and we thank you in advance for leaving a review! Don't forget to subscribe to hear about new episodes as they come out too. Thank you to our sponsor, the Canadian Consortium of Neurodegeneration in Aging, or CCNA, for their financial support of this podcast. This helps us to stay on the air and bring you high quality episodes. You can find out more about the CCNA on their website: https://ccna-ccnv.ca/. Our team of volunteers works tirelessly each month to bring you every episode of AMiNDR. This episode was scripted and hosted by Anusha Kamesh, edited by Chihiro Abe, and reviewed by Naila Kuhlmann. The bibliography was made by Rob Cloke and wordcloud was created by Salodin Al-Achkar (www.wordart.com). Big thanks to the sorting team for taking on the enormous task of sorting all of the Alzheimer's Disease papers into episodes each month. For November 2023, the sorters were Elyn Rowe, Christy Yu, Salodin Al-Achkar, Naila Kuhlmann and Anusha Kamesh. Also, props to our management team, which includes Sarah Louadi, Ellen Koch, Naila Kuhlmann, Elyn Rowe, Anusha Kamesh, Lara Onbasi, Joseph Liang, Judy Cheng, and Christy Yu, for keeping everything running smoothly. AMiNDR was founded in 2020 by Sarah Louadi, Ellen Koch, Elyn Rowe, and Naila Kuhlmann. Our music is from "Journey of a Neurotransmitter" by musician and fellow neuroscientist Anusha Kamesh; you can find the original piece and her other music on soundcloud under Anusha Kamesh or on her YouTube channel, AKMusic.   https://www.youtube.com/channel/UCMH7chrAdtCUZuGia16FR4w   -------------------------------------------------------------- If you are interested in joining the team, send us your CV by email. We are specifically looking for help with sorting abstracts by topic, abstract summaries and hosting, audio editing, creating bibliographies, and outreach/marketing. However, if you are interested in helping in other ways, don't hesitate to apply anyways.  --------------------------------------------------------------*About AMiNDR: *  Learn more about this project and the team behind it by listening to our first episode: "Welcome to AMiNDR!" 

The incredible Dr. Vibhav Bansal, Neuro-Intervention Medical Director, Javon Bea Hospital, in Rockford, IL, joins Atul to discuss Neurodegenerative diseases, and in particular, ALS, which affects nerve cells in the brain & spinal cord. There is no cure for ALS yet, an unforgiving illness, impacting all patients differently.  I wouldn't wish this to happen to any loved one, but it happened to my dear Mom, whom we lost in August of this year.  This episode is meant to drive awareness around ALS, an understanding of it, how we can support, and a celebration of my dear Mom. Part II in our Prof P Health Series: tips to help us create & curate a fulfilling life of value. 00:00 INTRO 03:36 Dr. Vibhav Bansal 08:40 ALS: what it is. 12:20 Deepak Mamu / India 14:36 EMG: testing the Integrity of the nerves, DNI 27:05 AI: help diagnose the disease earlier 28:55 How we can Help, ALS Foundation 36:30 Your body IS what YOU eat & consume 37:30 DNI and DNR: physical & cultural implications 42:30 Dr. Madhav Srivastava 47:50 How to Keep your Brain Sharp

Dr. Hett's research uses non-invasive MRI technology to investigate HD-related changes in the circulation of the fluid that bathes the nervous system, known as cerebrospinal fluid (CSF). By measuring the flow of CSF in people, Dr. Hett will attempt to understand better how it changes with HD, and, as a result, potentially determine how drug delivery methods might be tailored more personally. This novel idea emerged from a small pilot study, but could have major implications for the delivery of huntingtin-lowering therapies. If you are interested in participating in Dr. Hett's research, please reach out to me, and I will get you in touch with him. My email is lauren@help4hd.org.

Progressive decline in our brains and nervous system, more than other types of disease, truly challenges who we are as individual people. Neurodegenerative disorders such as Alzheimers, Parkinson's, Multiple Sclerosis and others are among the most feared possibilities we face. Join us for a two part discussion with neurologist Dr. Erik Ensrud to learn about the range of these diseases that affect millions of people. But more than a review, the message is that now, more than ever, we can do something about changing our risk of ever getting these diseases or the rate of progression if we do. As always, questions, comments & topic suggestions welcome at info@lastingimpactwellness.com Follow us on Instagram & Facebook @lastingimpactwellness Please be sure to subscribe, leave us a review & SHARE this podcast with others! We truly appreciate your support. Original music by EP3 Episode references: Alzheimer's Association Parkinson's Foundation Erickson KI, Raji CA, Lopez OL, Becker JT, Rosano C, Newman AB, Gach HM, Thompson PM, Ho AJ, Kuller LH. Physical activity predicts gray matter volume in late adulthood: the Cardiovascular Health Study. Neurology. 2010 Oct 19;75(16):1415-22. https://health.ucdavis.edu/news/headlines/volunteering-in-late-life-may-protect-the-brain-against-cognitive-decline-and-dementia/2023/07#:~:text=(Sacramento)%20Volunteering%20in%20late%20life,International%20Conference%202023%20in%20Amsterdam. Day SM, Gironda SC, Clarke CW, Snipes JA, Nicol NI, Kamran H, Vaughan W, Weiner JL, Macauley SL. Ethanol exposure alters Alzheimer's-related pathology, behavior, and metabolism in APP/PS1 mice. Neurobiol Dis. 2023 Feb;177:105967. Sabia S, Fayosse A, Dumurgier J, van Hees VT, Paquet C, Sommerlad A, Kivimäki M, Dugravot A, Singh-Manoux A. Association of sleep duration in middle and old age with incidence of dementia. Nat Commun. 2021 Apr 20;12(1):2289. Morris MC, Tangney CC, Wang Y, Sacks FM, Bennett DA, Aggarwal NT. MIND diet associated with reduced incidence of Alzheimer's disease. Alzheimers Dement. 2015 Sep;11(9):1007-14.